[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 634
1. Sandhu DS, Sandhu S, Karwasra RK, Marwah S: Profile of breast cancer patients at a tertiary care hospital in north India. Indian J Cancer; 2010 Jan-Mar;47(1):16-22
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profile of breast cancer patients at a tertiary care hospital in north India.
  • BACKGROUND AND AIMS: We carried out this study in order to know the epidemiology and management strategies for breast cancer patients in our patient population.
  • SETTINGS AND DESIGN: The epidemiological data pertaining to demography and risk factors for carcinoma breast were analyzed retrospectively in patients admitted to a tertiary care hospital of North India.
  • RESULTS: Mean age of our female breast cancer patients was found to be lower compared to the western world, with an average difference of one decade.
  • Lump in the breast was a dominant symptom.
  • Familial breast cancer was uncommon.
  • Left sided breast cancer was slightly preponderant.
  • Screening by mammography and staging procedures such as bone scan, Computed Tomography (CT) scan, and Magnetic Resonance Imaging (MRI) were sparsely used.
  • The most common histology was infiltrating duct carcinoma.
  • CONCLUSION: Modified radical mastectomy was found to be a safe operative procedure.
  • Breast conservative surgery, although considered the gold standard in early breast cancer, was found unsuitable for our patients, due to the social background and lack of intensive radiotherapy and chemotherapy backup.
  • Infiltrating duct carcinoma was more commonly associated with positive lymph nodes compared to other histopathologies.
  • Neoadjuvant chemotherapy was used mainly by surgical oncologists suggesting a more rational approach toward the management of breast carcinoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Breast Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / therapy. Combined Modality Therapy. Female. General Surgery / statistics & numerical data. Hospitals. Humans. India / epidemiology. Male. Mastectomy. Medical Oncology / statistics & numerical data. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Cancer. 2010 Jan-Mar;47(1):1-2 [20071780.001]
  • (PMID = 20071784.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Sharma S, Hiran KR, Pavithran K, Vijaykumar DK: A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study. World J Surg Oncol; 2009;7:35
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study.
  • BACKGROUND: Interest in translational studies aimed at investigating biologic markers in predicting response to primary chemotherapy (PCT) in breast cancer has progressively increased.
  • METHODS: Adult, non-pregnant, non-lactating women with histologically confirmed infiltrating duct carcinoma underwent serial core biopsies after first cycle of PCT and these were scored for Ki-67, Bcl-2 and Caspase-3 using immunohistochemistry.
  • RESULTS: We recruited 30 patients with a mean age of 51 years.
  • We were successful 95.6% times in performing a core biopsy and of these 84.6% had adequate tissue in the cores harvested.
  • Good responders had significantly higher Ki-67 and significantly lower Bcl-2 at baseline and a significant decrease in Ki-67 and Caspase-3 at 21 days after the first chemotherapy.
  • CONCLUSION: We report a detectable change in biomarkers as early as 24-48 hours after the first chemotherapy along with a definite trend in change that can possibly be used to predict response to chemotherapy in an individual patient.
  • [MeSH-major] Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Biomarkers. Caspase 3 / analysis. Female. Humans. Ki-67 Antigen / analysis. Middle Aged. Pilot Projects. Prospective Studies. Proto-Oncogene Proteins c-bcl-2 / analysis. Receptors, Estrogen / analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 1999 Mar;6(1):25-8 [10732783.001]
  • [Cites] Endocr Relat Cancer. 1999 Mar;6(1):29-40 [10732784.001]
  • [Cites] Endocr Relat Cancer. 1999 Mar;6(1):61-8 [10732789.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(30):96-102 [11773300.001]
  • [Cites] Oncologist. 2002;7(3):239-45 [12065797.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):124-33 [12538460.001]
  • [Cites] Breast. 2003 Oct;12(5):320-7 [14659147.001]
  • [Cites] Breast Cancer Res Treat. 2003 Nov;82(2):113-23 [14692655.001]
  • [Cites] Arch Surg. 1989 Jan;124(1):21-5 [2910244.001]
  • [Cites] Breast Cancer Res Treat. 1990 May;15(3):137-47 [2372569.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1253-9 [8080512.001]
  • [Cites] Eur J Cancer. 1994;30A(14):2068-73 [7857705.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4471-8 [7671262.001]
  • [Cites] J Clin Invest. 1996 Jun 1;97(11):2403-4 [8647929.001]
  • [Cites] Lancet. 1997 Mar 22;349(9055):849 [9121265.001]
  • [Cites] Acta Oncol. 1997;36(4):369-74 [9247096.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):621-6 [9484820.001]
  • [Cites] Breast Cancer Res Treat. 1998 Mar;48(1):11-20 [9541185.001]
  • [Cites] Breast Cancer Res Treat. 1998 Mar;48(2):107-16 [9596482.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):593-600 [9815725.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(1):51-9 [10206072.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3058-63 [10506600.001]
  • [Cites] Radiat Med. 2005 May;23(3):189-94 [15940066.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):869-74 [17012049.001]
  • [Cites] Surg Oncol. 2008 Dec;17(4):301-11 [18467090.001]
  • (PMID = 19331661.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Estrogen; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2669088
  •  go-up   go-down


3. Kumar A, Singh S, Pradhan S, Shukla RC, Ansari MA, Singh TB, Shyam R, Gupta S: Doppler ultrasound scoring to predict chemotherapeutic response in advanced breast cancer. World J Surg Oncol; 2007;5:99

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doppler ultrasound scoring to predict chemotherapeutic response in advanced breast cancer.
  • BACKGROUND: Doppler ultrasonography (US) is increasingly being utilized as an imaging modality in breast cancer.
  • Neoadjuvant chemotherapy is the standard modality of treatment in locally advanced breast cancer.
  • Histological examination remains the gold standard to assess the chemotherapy response.
  • However, based on the color Doppler findings, a new scoring system that could predict histological response following chemotherapy is proposed.
  • METHODS: Fifty cases of locally advanced infiltrating duct carcinoma of the breast were studied.
  • All patients underwent clinical, Doppler and histopathological assessment followed by three cycles of CAF (Cyclophosphamide, Adriamycin and 5-Fluorouracil) chemotherapy, repeat clinical and Doppler examination and surgery.
  • Higher scores corresponded with a more favorable histopathological response.
  • Twenty four patients had complete response to chemotherapy.
  • CONCLUSION: Doppler scoring can be accurately used to objectively predict the response to chemotherapy in patients with locally advanced breast cancer and it correlates well with histopathological response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2003 Oct;186(4):404-8 [14553860.001]
  • [Cites] Am J Surg. 2003 Oct;186(4):337-43 [14553846.001]
  • [Cites] Breast Cancer Res Treat. 2001 Sep;69(2):143-51 [11759820.001]
  • [Cites] Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1998 Dec;20(6):454-8 [11717939.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):3073-9 [10898354.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2410-23 [10357412.001]
  • [Cites] Eur J Radiol. 1998 May;27(2):149-52 [9639141.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Ultrasound Med. 2005 Jul;24(7):885-95 [15972702.001]
  • [Cites] Breast Cancer. 2005;12(1):45-51 [15657523.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):595-9 [15816633.001]
  • (PMID = 17725837.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2008196
  •  go-up   go-down


Advertisement
4. Agrawal R: Synchronous dual malignancy: successfully treated cases. J Cancer Res Ther; 2007 Jul-Sep;3(3):153-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of a second malignancy in a patient with a known malignant tumour is not uncommon.
  • Case report 1-A 70 year old female presented to us with lump in right breast for two years and bleeding per vaginum for two years.
  • Histopathology of cervix showed squamous cell carcinoma (large cell non keratinizing) and clinical stage was IIIB.
  • HPE mastectomy specimen showed infiltrating duct carcinoma and stage II.
  • Patient was treated with external beam radiotherapy for carcinoma cervix and breast simultaneously and chemotherapy as required.
  • Patient is on regular follow up and clinically no evidence of disease.
  • HPE brain tissue showed astrocytoma grade II and HPE parotid tumour showed low grade muco-epidermoid carcinoma.
  • Patient is in regular follow up,having no complain,clinically no neurological dysfunction and no evidence of disease at right parotid and neck region.
  • Thus it was concluded that patients responded well to treatment.
  • Treatment strategies in case of synchronous double malignancy depend on treating the malignancy that is more advanced first or sometimes both could be treated simultaneously.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Treatment Outcome


5. Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J, Wang W: Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer; 2005 Sep 20;116(5):799-807
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential anticancer activity of tanshinone IIA against human breast cancer.
  • It has antioxidant properties and cytotoxic activity against multiple human cancer cell lines, inducing apoptosis and differentiation of some human cancer cell lines.
  • Our purpose was to confirm its anticancer activity on human breast cancer in vitro and in vivo and to elucidate the mechanism of its activity.
  • Human breast cancer cells were tested in vitro for cytotoxicity, colony formation inhibition, BrdU incorporation and gene expression profiling after treatment with tanshinone IIA.
  • Seven nude mice bearing human breast infiltrating duct carcinoma orthotopically were tested for anticancer activity and expression of caspase-3 in vivo by s.c. injection of tanshinone IIA at a dose of 30 mg/kg 3 times/week for 10 weeks.
  • Tanshinone IIA demonstrated a dose- and time-dependent inhibitory effect on cell growth (IC50 = 0.25 microg/ml), and it significantly inhibited colony formation and BrdU incorporation of human breast cancer cells.
  • Oligonucleotide microarray analysis identified 41 upregulated (1.22%) and 24 downregulated (0.71%) genes after tanshinone IIA treatment.
  • Upregulated genes were involved predominantly in cycle regulation, cell proliferation, apoptosis, signal transduction and transcriptional regulation; and downregulated genes were associated mainly with apoptosis and extracellular matrix/adhesion molecules.
  • Our findings suggest that tanshinone IIA might have potential anticancer activity on both ER-positive and -negative breast cancers, which could be attributed in part to its inhibition of proliferation and apoptosis induction of cancer cells through upregulation and downregulation of multiple genes involved in cell cycle regulation, cell proliferation, apoptosis, signal transduction, transcriptional regulation, angiogenesis, invasive potential and metastatic potential of cancer cells.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / drug therapy. Phenanthrenes / pharmacology
  • [MeSH-minor] Animals. Caspase 3. Caspases / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Diterpenes, Abietane. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Neoplasm Transplantation. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15849732.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Diterpenes, Abietane; 0 / Phenanthrenes; 03UUH3J385 / tanshinone; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


6. Morvan A, de Korvin B, Bouriel C, Carsin A, Tas P, Bendavid C, Dupré PF, Kerbrat P, Mesbah H, Poree P, Levêque J: [MRI evaluation of residual breast carcinoma after neoadjuvant chemotherapy]. J Radiol; 2010 Jun;91(6):693-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MRI evaluation of residual breast carcinoma after neoadjuvant chemotherapy].
  • [Transliterated title] Cancer du sein traité par chimiothérapie néoadjuvante: évaluation du reliquat tumoral par l'IRM mammaire.
  • PURPOSE: This study aims to evaluate the sensibility and specificity of MRI in the detection and size measuring of residual breast cancer in patients treated with neoadjuvant chemotherapy before surgery.
  • PATIENTS AND METHODS: This is a retrospective study of 32 women, who underwent breast MRI before and after neoadjuvant treatment.
  • RESULTS: The sensibility of MRI to assess pathologic Complete Response (no invasive residual tumor) was excellent (100%) but the specificity was low (55,5%).
  • There was no false negative case and four false positive cases (Two ductal carcinomas in situ and two scars-like fibrosis).
  • When MRI outcomes were compared with the presence or absence of invasive or in situ residual carcinoma, only one false negative case was noticed (one "in situ" residual tumor).
  • Underestimations of tumor size were due to non-continuous tumor regression or invasive lobular carcinoma or association of invasive carcinoma and intra ductal breast cancer.
  • Over estimations of tumor size were due to chemotherapy-induced changes.
  • CONCLUSION: MRI is a sensitive but poorly specific method to assess the pathological complete response after neoadjuvant chemotherapy.
  • Estimation of tumor size and detection of isolated residual in situ carcinoma are fare.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / drug therapy. Magnetic Resonance Imaging. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoadjuvant Therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20808270.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Afsar NA, Kulsoom B, Mateen A, Ahmed S, Tahseen M, Ahmed A: Breast cancer pattern and chemotherapy response--an institutional study in Pakistan. Asian Pac J Cancer Prev; 2010;11(3):825-30
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer pattern and chemotherapy response--an institutional study in Pakistan.
  • BACKGROUND: This study was planned to audit female breast cancers and their chemotherapy in a busy public sector institution.
  • RESULTS: A total of 3,431 female breast cancer patients presented during 2001-2008, half being <45 years, mostly suffering from infiltrating ductal carcinoma of breast.
  • Further analyzing a subgroup of 183 consecutive patients over six months revealed that only 1.6% were at stage-I, whereas 75% had node-positive disease, including 19.1% with distant metastases.
  • 5-Flourouracil, doxorubicin and cyclophosphamide (FAC) constituted the most common chemotherapy.
  • Overall, 33% developed myelotoxicity, more often if age ≥ 45 years (p=0.012), out of which 60% needed active correction.
  • CONCLUSIONS: Infiltrating ductal carcinoma of the breast is the most common type.
  • FAC is the most common chemotherapy.
  • Tendency for late diagnosis, metastatic disease, treatment failure as well as leukopenia especially in ≥ 45 years is present.
  • Failure to show leukopenia is suggestive of poor therapeutic outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039062.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


8. Lemos LB, Qu Z, Garg K, Papasozomenos S: Pseudoneoplastic proliferation of histiocytes with paclitaxel-induced ultrastructural changes in a mastectomy specimen. Ann Diagn Pathol; 2004 Oct;8(5):299-304
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 49-year-old Hispanic woman with a T4N1M0 infiltrating duct carcinoma of the left breast underwent four courses of FAC (doxorubicin 86 mg, 5-fluorouracil 860 mg, cyclophosphamide 86 mg, and dexamethasone 10 mg) adjuvant chemotherapy plus four courses of paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ) and subsequent mastectomy.
  • The tumor shrunk from 6.5 cm to 2.5 cm after the treatment.
  • The tumor showed typical chemotherapy changes and a massive proliferation of histiocytes that mimicked a neoplasm.
  • A nodular proliferation of the same cells in one axillary node raised the impression of a second malignant tumor in the breast spreading to the node.
  • These findings ruled out histiocytoid carcinoma, granular cell tumor, and Erdheim-Chester disease.
  • The treated breast carcinoma cells were tubulin-positive but the proliferating histiocytes were tubulin-negative.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Histiocytes / ultrastructure. Mastectomy. Paclitaxel / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor. Cell Proliferation / drug effects. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Intermediate Filaments / drug effects. Intermediate Filaments / ultrastructure. Lymph Nodes / pathology. Lymphatic Metastasis. Mastectomy, Modified Radical. Middle Aged. Sentinel Lymph Node Biopsy. Tubulin / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15494938.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Tubulin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; CAF protocol
  •  go-up   go-down


9. Saxena S, Beena KR, Bansal A, Bhatnagar A: Emperipolesis in a common breast malignancy. A case report. Acta Cytol; 2002 Sep-Oct;46(5):883-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emperipolesis in a common breast malignancy. A case report.
  • The present report describes this unusual observation within epithelial cancer cells of the breast.
  • CASE: A 52-year-old female presented with a hard, adherent lump over the right breast for one year.
  • Fine needle aspiration and histopathologic examination of the tumor showed features of infiltrating duct carcinoma with emperipolesis as a striking feature of the tumor cells.
  • The tumor showed a near-total response to neoadjuvant chemotherapy.
  • CONCLUSION: The mechanism and biologic significance of emperipolesis in producing a near-total response to neoadjuvant chemotherapy in the present case suggest its role in inducing a tumoricidal effect, possibly involving a cascade of chemokines.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Leukocytes, Mononuclear / pathology
  • [MeSH-minor] Antigens, Neoplasm / analysis. Antigens, Neoplasm / immunology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cytoplasm / pathology. Epithelial Cells / pathology. Female. Fibrosis. Fluorouracil / administration & dosage. Humans. Hyperplasia / pathology. Immunohistochemistry. Keratins / analysis. Keratins / immunology. Methotrexate / administration & dosage. Middle Aged. Vacuoles / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12365224.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 68238-35-7 / Keratins; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  •  go-up   go-down


10. Misra AK, Mishra A, Agrawal G, Agarwal A, Mishra SK: Occult breast carcinoma: a report of four cases and review of literature. Indian J Cancer; 2001 Mar;38(1):49-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult breast carcinoma: a report of four cases and review of literature.
  • We report four occult carcinoma breast cases in which extensive axillary node metastases was the first manifestation.
  • Primary tumor could be found in three patients, one had squamous cell carcinoma (SCC) & two had infiltrating duct carcinoma (IDC).
  • However primary tumor was not detected in breast tissue of the fourth patient.
  • All patient received postoperative radiotherapy and chemotherapy.
  • We have reviewed the literature and discussed the approach to diagnosis and management in female patients presenting with metastatic carcinoma in the axillary nodes with emphasis on the appropriate pre-treatment evaluation.
  • [MeSH-major] Breast Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14758886.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 13
  •  go-up   go-down


11. Prasad ML, Osborne MP, Giri DD, Hoda SA: Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol; 2000 Mar;24(3):422-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases.
  • Clinicopathologic data on microinvasive carcinoma of the breast (MICB) as defined by the 1997 TNM criteria (T1mic < or = 1 mm) is scarce.
  • MICB was ductal in 18 patients, including one tubular carcinoma, and was lobular in three patients.
  • The mean number of invasive foci was two per patient (range, one to seven foci).
  • The accompanying duct carcinoma in situ had high-grade nuclei and necrosis in 16 of 18 patients (89%), 13 of which (72%) were comedo-type.
  • Eleven patients underwent mastectomy, nine received radiation therapy, one received chemotherapy, and two underwent lumpectomy only.
  • One patient had a chest wall recurrence of infiltrating duct carcinoma and another recurred with duct carcinoma in situ.
  • [MeSH-major] Breast Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10716157.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


12. Paciucci PA, Raptis G, Bleiweiss I, Weltz C, Lehrer D, Gurry R: Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer. Anticancer Drugs; 2002 Sep;13(8):791-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer.
  • Neo-adjuvant, dose-dense docetaxel, 100 mg/m(2) every 2 weeks x 4 cycles, was administered to 12 patients with locally advance breast cancer (LABC) (10 stage IIIa and three stage IIIb).
  • Eligibility requirements included a PS 0-2, normal hepatic and renal function, and radiologic absence of metastatic disease.
  • Filgrastim [granulocyte colony stimulating factor (G-CSF)] was started 1 day after chemotherapy and was given for 6 days.
  • The median age was 45 (range 34-73) and pre-treatment pathology revealed poorly differentiated infiltrating duct carcinoma in 11 and infiltrating lobular cancer in one, with positive ER/PR status in five.
  • Three patients (of whom two with stage IIIb) had progressive disease and went on to receive neo-adjuvant therapy with AC.
  • There were two instances of grade 3 extra-hematologic toxicity: one patient had severe pain and one had treatment-related fatigue.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Granulocyte Colony-Stimulating Factor / administration & dosage. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Female. Filgrastim. Humans. Middle Aged. Neoadjuvant Therapy. Recombinant Proteins

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12394262.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 0 / Taxoids; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


13. Gercovich N, Gil Deza E, Russo M, Garcia Gerardi C, Diaz C, Morgenfeld E, Rolnik B, Emina J, Rivarola E, Gercovich FG: Early-stage male breast cancer: A 10-year experience. J Clin Oncol; 2009 May 20;27(15_suppl):e11630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage male breast cancer: A 10-year experience.
  • : e11630 Introduction: Male breast cancer is very rare, representing only between 0.7% and 1% of all breast cancers, and only half of them are early stage cases.
  • OBJECTIVE: The present study has been designed with the aim of studying retrospectively the clinical onset and evolution of male invasive breast cancer patients (stages I and II) treated at IOHM between 1997 and 2008.
  • METHODS: The records of 3,000 breast cancer cases followed between 1997 and 2008 were searched, looking for male stage I and II breast cancer patients.
  • The information registered encompassed: adjuvant treatments, recurrence date and date of final consultation or death.
  • Tumoral type= Invasive Ductal Carcinoma 12 pt.
  • Tumoral subtype= NOS 9 pt (75%) Apocrine 2 pt (17%) Micropapillar 1 pt (8%).
  • Adjuvance= No=2 pt, Hormonotherapy (HT)= 3 pt, Chemotherapy (CHT) = 3 pt, CHT+HT= 4 pt.
  • Mean Time To Progression= Stage I =66 months, Stage II =42 months.
  • Twelve stage I and II male breast cancer patients were identified out of 3000 (0.4%) breast cancer cases diagnosed and followed in the past 10 years at the IOHM.
  • 2. Mastectomy was the surgical procedure in 11 of the 12 cases 3.
  • Ten pt underwent adjuvant treatment.
  • 4. With a mean follow up time of 60 months, all stage I patients are alive and there were no recurrences.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961181.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Mates M, Hopman W, Madarnas Y: Patterns of care and outcomes of locally advanced breast cancer at the Cancer Centre of Southeastern Ontario. J Clin Oncol; 2009 May 20;27(15_suppl):e11614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of care and outcomes of locally advanced breast cancer at the Cancer Centre of Southeastern Ontario.
  • : e11614 Background: Preoperative chemotherapy (PCT) is the standard of care for locally advanced breast cancer (LABC).
  • As part of a multicentre provincial initiative we undertook a review of practice patterns and outcomes for women with LABC at our institution.
  • METHODS: We reviewed electronic and paper records for M<sub>0</sub> pts receiving PCT for LABC between 1995-2007 at our institution, collecting demographic, disease and treatment-related, and outcome variables.
  • Stage distribution: 10% IIB, 11% IIIA, 77% IIIB and 2% IIIC, of which 45% had inflammatory breast cancer (IBC).
  • At biopsy 90% were invasive ductal carcinoma, 36% were ER and PR(-) and 25% were her2(+).
  • Median time from surgical consultation to PCT was 22d (6-126).
  • PCT was anthracycline-based alone in 85% of pts, 8% received a taxane, 3% also received preop endocrine therapy (ET), no pts received trastuzumab (T) preop.
  • Local therapy: mastectomy (M) in 82% of pts and partial M in 11%.
  • Axillary surgery was done in only 92% of pts (axillary node dissection 90%, sentinel node biopsy 1pt) and 7% had no definitive breast or axillary surgery due to local progression (3) or refusal (1).
  • Postop systemic therapy: CT in 5% of pts, ET in 65% and T in 10% of pts.
  • At definitive surgery 10% of pts had no residual disease in breast or axilla and 3 pts had only DCIS present, for a pathologic (p)CR rate of 15% using MDACC criteria.
  • Median 5y DFS was not reached for the entire population and those with a pCR vs. 26mo for pts with IBC; corresponding 5y DFS rates were 58%, 78%, and 41% respectively.
  • Median 5y OS was for the entire population was 52mo vs. 48mo for pts with a pCR and 47mo in the IBC group; corresponding 5y OS rates were 62%, 78% and 44% respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961135.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Tamura N, Tamura N: Prognostic factors for patients with invasive ductal carcinoma of the breast who received neoadjuvant chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e11617

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for patients with invasive ductal carcinoma of the breast who received neoadjuvant chemotherapy.
  • : e11617 Background: Neoadjuvant chemotherapy (NAC) for patients with invasive ductal carcinoma (IDC) of the breast is performed as a standard therapy in many hospitals for improving outcomes of IDC patients.
  • Tumor necrosis in primary-invasive-tumors was a significant factor for tumor recurrence of patients in the both.
  • CONCLUSIONS: The study clearly demonstrated that grading system for LVTE, and characteristics of nodal metastatic tumors as well as the presence of tumor necrosis in primary-invasive tumors are very important prognostic factors for IDC patients who received NAC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961152.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Gumus M, Ustaalioglu BO, Seker M, Bilici A, Salman T, Sönmez B, Aliustaoglu M, Eser M, Salepci T, Yaylaci M: Single-center experiences of neoadjuvant systemic therapy in breast cancer: Individualization of the treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e11628

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-center experiences of neoadjuvant systemic therapy in breast cancer: Individualization of the treatment.
  • : e11628 Background: Neoadjuvant chemotherapy is one of the standard treatment options for patients with locally advanced breast cancer for twenty five years.
  • In this study, we evaluate results of neoadjuvant chemotherapy in breast cancer patients.
  • METHODS: We retrospectively analyzed 68 patients with locally advanced breast cancer.
  • Anthracycline/taxane-based chemotherapy regimens were prescribed mostly for neoadjuvant chemotherapy.
  • Before chemotherapy was given, patients were examined for distant metastasis by radiologic methods thereafter if patient had distant metastasis, they were excluded.
  • Patients with breast cancer received neoadjuvant chemotherapy were analyzed according to age, menopausal status, type of surgery, response to the treatment, histopathological properties and survival.
  • After 3 to 6 cycle of chemotherapy patients were reevaluated by clinically and radiologically for response.
  • Surgery was performed for appropriate patient thereafter adjuvant locoregional and systemic chemotherapy were continued.
  • Median follow-up time was 19 month.
  • After 3 to 6 cycle of neoadjuvant chemotherapy 64 of patients responded to therapy (94,1 %).
  • Breast conserving surgery was performed for 15,6 % patients.
  • In histopathologic analysis most of patients were invasive ductal carcinoma and there was lymph node invasion for 84,9 %.
  • Median disease free survival time was 44 month (SE: 9; 95% CI: 25-62) but median overall survival time could not be reached.
  • Three years disease free survival rate and overall survival rate were 55,3% and 90,1% respectively.
  • According to Cox regression analyses; we did not find any demographic and pathologic characteristic of breast cancer that is related to prognosis.
  • CONCLUSIONS: In recent years neoadjuvant chemotherapy in breast cancer is increasingly being used for early stage disease.
  • Further study will be facilitated establishment of guidelines for preselecting patients for neoadjuvant chemotherapy and will provide beneficial effect on treatment option and survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961123.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Sircar T, Chaudhri S, Francis A: Effect of neoadjuvant chemotherapy on oestrogen, progesterone, and HER-2 receptor expression in breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of neoadjuvant chemotherapy on oestrogen, progesterone, and HER-2 receptor expression in breast cancer.
  • : e11588 Background: Neoadjuvant chemotherapy(NC) is used in treating locally advanced operable breast cancer.
  • After surgery, further adjuvant treatment is offered based on the estrogen receptor (ER), progesterone receptor (PR) and HER2 status.
  • Treatment post operatively can be based on the ER/PR/HER2 status of the core biopsy taken preoperatively.
  • However a change in ER/PR or HER2 status following NC could have a profound effect on adjuvant treatment with the real possibility of appropriate therapy being unknowingly withheld.
  • The aim of our study was to determine the percentage of patients whose ER/PR, HER2 receptor expression change with NC and if these changes lead to change in their adjuvant treatment.
  • METHODS: This is a retrospective study of 32 patients with locally advanced breast cancer who had NC followed by breast conservation surgery or mastectomy.
  • RESULTS: After NC, 5 patients had complete pathological response and 2 patients had residual ductal carcinoma in situ.
  • 25(78%) patients had residual invasive malignancy.
  • CONCLUSIONS: Change in 1 patient(4%) from HER2 negative to HER2 positive lead to change in adjuvant treatment who would have otherwise not received transzutumab.Q scores changed in 24% and 40% for ER and PR respectively, however, no change was observed with regards to hormonal adjuvant treatment.
  • A study with a bigger cohort might address this issue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964117.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Rodriguez Franco C, Aguiar Bujanda D, Saura Grau S, Bohn Sarmiento U, Aguiar Morales J: Male breast cancer retrospective institution review of a 17-year period. J Clin Oncol; 2009 May 20;27(15_suppl):e11638

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast cancer retrospective institution review of a 17-year period.
  • : e11638 Background: Male breast cancer (MBC) is a very uncommon illness relative to female breast cancer (FBC) The are some differences between both that could influence the management, like gene expression, hormonal enviroment and anatomy of the gland.
  • RESULTS: There were 22 male patients diagnosed in our institution with a median age of 62.4 years (range 34 to 83 years) during the period.
  • One had bilateral breast cancer.
  • Stage of disease was I-II in 13 patients (59%), III in 8 patients (36%), and IV in 1 patient (5%).
  • Five patients (22.7%) had familiar history of breast cancer and 3 patients (13%) had familiar history of other kind of neoplasias.
  • Ductal carcinoma was the predominant histologic subtype with 17 patients (77%).
  • Other types were pleomorfic, mucoid and papilar carcinoma (one each type) and 3 patients with intrapapilar carcinoma with microinfiltration.
  • Surgery was the initial treatment in 18 patients (81%), just 2 of them performing tumorectomy and the other 16 radical mastectomy.
  • 3 patients receive neoadyuvant chemotherapy with 1 complete response and one partial response.
  • 13 patients (59%) received adjuvant radiotherapy (RT) and 17 (77%) adjuvant hormonal therapy (HT) mostly of them with tamoxifen (14/17) and the others 3 patients with aromatase inhibitors.
  • Adjuvant chemotherapy was used in 9 (41%) patients with an antracycline regimen.
  • With a median follow-up of 78 months (range 7-125), overall survival was 77 % with 3 patients died with progression disease and two patients died because of intercurrent illness without evidence of cancer progression.
  • Most cases can be treated with radical intention with surgery (mostly radical) and adjuvant treatment with a good survival percentage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961210.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Zeichner I, Flores D, Munoz D, Ramirez MT: Impact of socioeconomic status on survival in breast cancer patients with ten and more positive lymph nodes. J Clin Oncol; 2004 Jul 15;22(14_suppl):9730

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of socioeconomic status on survival in breast cancer patients with ten and more positive lymph nodes.
  • The objective of our study was to evaluate the impact of socioeconomic status on survival among a group of bad prognosis breast cancer patients Methods: The clinical records of patients with breast cancer clinical stage II from 1983-1992 were reviewed.
  • Under the older clinical staging, a group of 52 patients with ten or more positive nodes, complete treatment and follow up was identified.
  • Socioeconomic data, tumor characteristics, treatment, results and follow up were recorded and analyzed.
  • All the tumors were invasive ductal carcinomas.
  • Adjuvant chemotherapy with FAC was given to 7 in group 1(31.8%) and 12 (40%) in the other; CFM was given to 15 ( 68.2) in group 1 and 14 (46.7%) in group 2 and in the latter, 4 (13.3) with 5Fu and Ciclophosfamide alone.
  • Mean survival time was of 44 months for group 1 and 167 months for group 2 p=0.004 Conclusions: With the results obtained, we can conclude that in this group of patients, with same characteristics and treatment uniformity, the only explication for the significant differences in survival that we observed are directly related to the socioeconomic status, and therefore, more attention has to be paid on this subject.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014370.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Ahmed S, Shahid RK: Acute interstitial pneumonitis following adjuvant tamoxifen therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e11637

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute interstitial pneumonitis following adjuvant tamoxifen therapy.
  • : e11637 Background: Tamoxifen is a serum estrogen receptor modulator that is widely used in the treatment of women with breast cancer and has a low incidence of serious side-effects.
  • OBJECTIVE: To report an unusual case of acute interstitial pneumonitis in a patient with early stage breast cancer treated with tamoxifen.
  • RESULTS: A 66 year old post-menopausal woman with past medical history of type 2 diabetes mellitus, and hypertension noted a lump in the right breast.
  • An excision biopsy revealed 9 mm moderately differentiated invasive ductal carcinoma.
  • Her other medication were metformin, valsartan, calcium and vitamin D.
  • She developed acute respiratory failure requiring intubation and mechanical ventilation.
  • CONCLUSIONS: Drug-induced lung injuries are usually idiosyncratic reactions and occur in an unpredictable manner.
  • The presence of a temporal relationship between the lung injury and tamoxifen administration, a rapid clinical improvement after discontinuation of the drug, and absence of other causes strongly implicated tamoxifen as a potential cause of acute lung injury.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961192.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Perkins GH, Green MC, Middleton LP, Giordano SH, Garcia SM, Strom EA, Schechter NR, Allen P, Buchholz TA, Hortobagyi GN: Medullary breast carcinoma: Outcomes and prognosis with the utilization of chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):671

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medullary breast carcinoma: Outcomes and prognosis with the utilization of chemotherapy.
  • : 671 Background: Medullary carcinoma of the breast is an uncommon histological type consisting of poorly differentiated cells surrounded by a prominent lymphoid stroma.
  • It is also suggested that these lesions have good prognosis and therefore may not benefit from systemic therapy.
  • We therefore report on our experience with this tumor type.
  • Outcomes were analyzed by administration of chemotherapy, use of hormonal therapy, pathologic size, and nodal status.
  • RESULTS: Mean age at diagnosis was 44 years (range 24-84)with a mean follow-up of 9 years (range 0.16- 23.3).
  • 71% of patients recieved chemotherapy (n=102) with 88% having a doxorubicin-based regimen.
  • Improvement in 5 and 10 yr OS and DMFS was noted with chemotherapy (86%/79%) vs no chemoherapy (72%/66% P=.08) and ( 81%/81% vs 71%/71% P=.08).
  • No improvement was noted with adjuvant hormonal therapy (n=21)(P=.5).
  • LN- patients likewise had improved 5 and 10 yr OS rates (87%/80% vs 75%/61%)(P=.07).
  • CONCLUSIONS: Patients with medullary breast cancer benefited from the use of adjuvant chemotherapy.
  • In our series, patients with + nodes and tumor size greater than 1 cm had prognosis similar to that ascribed to invasive ductal carcinoma NOS and may benefit from systemic regimens.
  • Larger datasets should be examined to further clarify therapy recommendations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017003.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Imoto S, Morita S, Kitajima M, Aikou T, Kitagawa Y, Japanese Society Investigators for Sentinel Node Navigation Surgery: Early recurrence of breast cancer after sentinel node navigation surgery: A multicenter prospective study in Japan. J Clin Oncol; 2009 May 20;27(15_suppl):e11530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early recurrence of breast cancer after sentinel node navigation surgery: A multicenter prospective study in Japan.
  • : e11530 Background: To assess lymphatic mapping technique and prognosis after sentinel node navigation surgery (SNNS), the Japanese society for SNNS conducted a non-randomized multi-center prospective study on SNNS in early breast cancer.
  • As 46 cases were withdrawn for some reasons and 11 cases were diagnosed as benign disease, 1,411 cases were entered in this study and will be observed until 2010.
  • Seven cases died of disease.
  • From the patient background, 50 cases had invasive ductal carcinoma, one had non-invasive ductal carcinoma, and three had special type.
  • Fifty-two cases received chemotherapy and/or endocrine therapy.
  • SNNS in breast cancer is reliable to optimize surgical management in the axilla without increase of regional recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Chollet PJ, Dubray P, Durando X, Abrial C, Nayl B, Mouret-Reynier M, Pomel C, Bellière A, Lemery S, Penault-Llorca F: Pathologic complete response (pCR) in HER2 positive breast cancer to sequential FEC 100-docetaxel (D) plus trastuzumab (T) neoadjuvant chemotherapy (NCT). J Clin Oncol; 2009 May 20;27(15_suppl):e11560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic complete response (pCR) in HER2 positive breast cancer to sequential FEC 100-docetaxel (D) plus trastuzumab (T) neoadjuvant chemotherapy (NCT).
  • : e11560 Background: Trastuzumab plus chemotherapy has become the standard of care for Her-2-positive breast cancer.
  • METHODS: 21 patients (pts) with Her2-positive breast cancer (defined as either immunohistochemical 3+ or fluorescence in situ hybridization-positive) from June 2006 to September 2008 with breast cancer received 3 cycles (c) of FEC 100 ( epirubicin 100 mg/m<sup>2</sup> + 5-fluorouracil and cyclophosphamide 500mg/m<sup>2</sup>) followed by 3 c of D (100mg/m<sup>2</sup>) every 3 weeks +T 2mg/kg weekly or 6mg/kg every 3 weeks (9 weeks of T).
  • A clinical, mammography and ultrasound breast evaluation was performed at baseline, after 3 or 4 c and before surgery.
  • All pts had a ductal carcinoma.
  • 5 pts had inflammatory breast cancer.
  • 13 pts (62%) underwent breast-conserving surgery.
  • At the time of the analysis for cardiac evaluation, 8 pts continued to receive adjuvant T. 1 pt was lost for follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964071.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Jouhadi H Sr, Benider A: Adjuvant paclitaxel, capecitabine, and trastuzumab for HER-positive breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant paclitaxel, capecitabine, and trastuzumab for HER-positive breast cancer.
  • : e11526 Background: Anthracyclines are integral components of most adjuvant chemotherapy regimens for surgically removed early breast cancer and are central to the accepted treatment standards.
  • Recently the standard anthracycline regimen of doxorubicin plus cyclophosphamide was found to be inferior in preventing recurrence of breast cancer when compared to cyclophosphamide and docetaxel, questioning the necessity to expose patients to the potential cardiotoxicity of anthracycline in the adjuvant setting.
  • Trastuzumab, cornerstone of treatment of breast cancers that overexpress HER2 produces Unfortunately, in combination with anthracyclines a high incidence of cardiotoxicity as seen in early trials of metastatic breast cancer.
  • The trastuzumab adjuvant trial 006 from the Breast Cancer International Research Group shows for the first time that a nonanthracycline-containing regimen with trastuzumab has equivalent efficacy in decreasing the recurrence of breast cancer, with less incidence of cardiotoxicity when compared to anthracycline-containing trastuzumab adjuvant regimens.
  • METHODS: Our trial compared two adjuvant schemas of adjuvant chemotherapy arm1: paclitaxel(day 1-day 21: 6 courses), capecitabine(day1 to day 14: 6 courses) and trastuzumab (day 1 to day 21 for one year).
  • Arm2: 4AC plus 4 TH plus trastuzumab for one year.
  • INCLUSION CRITERIA: HER positive invasive ductal carcinoma, no lymphe node invaded at axillary dissection and no metatstasis, Negative ER and PR receptors Goal of study: evaluate efficacy and cardiac toxicity Results: From 2004 to 2005: 30 patient were included in each arm.
  • After 3 years: DFS was respectively 93% in first arm and 90% in Second arm Four women developed severe cardiac toxicity in arm 2 versus no one in arm1 Conclusions: There is no difference in efficacy between the two arms but a significant increase in cardiac toxicity in the second arm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964623.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Rejiv R, Biswajit D, Neelesh R, Sridevi V, Sagar TG, Shanta V: Breast cancer in young women less than 30 years from southern India: Study on clinical profile and outcome. J Clin Oncol; 2009 May 20;27(15_suppl):e22196

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer in young women less than 30 years from southern India: Study on clinical profile and outcome.
  • : e22196 Background: Breast cancer in young patients have an aggressive behaviour with poorer outcome.
  • METHODS: 213 Patients under the age of 30 years with breast cancer were studied for Demographics, clinical presentations, pathological profiles, treatment and survival.
  • Family history of breast and ovarian cases were seen in 6.6% of the patients.
  • Non infiltratring ductal carcinoma histopathology was noted in 13.6%.
  • Of 201 (94.3%) patients who received chemotherapy anthracycline based chemotherapy was delivered in 30.3%.
  • CONCLUSIONS: Very young Indian patients less than 30 years constitute a unique subset of breast cancer patients with majority being hormone receptor negative and locally advanced stage at presentation.
  • The over all outcome is inferior compared to older patients with breast cancer.
  • More aggressive adjuvant treatment may help in improving survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963634.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Davidson RS, Chaudhry M, Localio R, Schnall MD, Domchek SM: Predicting the extent of invasive disease by MRI to enhance the use of minimally invasive techniques in the management of early stage breast carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):610

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting the extent of invasive disease by MRI to enhance the use of minimally invasive techniques in the management of early stage breast carcinoma.
  • : 610 Background: With the advent of minimally invasive procedures such as radio-frequency ablation and vacuum-assisted core biopsy for managing early-stage invasive breast carcinoma, the ability to predict invasive disease by pre-procedure imaging is essential to achieving an adequate margin and for guiding adjuvant therapy.
  • Magnetic resonance imaging (MRI) is a sensitive modality used in the detection of breast pathology and may provide the anatomic resolution necessary to predict the extent of invasive disease.
  • METHODS: A retrospective review was conducted on MRI and pathologic data from 24 (63%) of 38 patients with focal, invasive breast carcinoma enrolled in an ongoing multi-modality imaging study between 3/02 and 10/03.
  • 1) 1 or 2 suspicious focal lesions per breast detected on MRI, 2) 1 or 2 pathologically-proven foci of invasive carcinoma per breast, and 3) no chemotherapy between MRI and definitive surgery.
  • Largest tumor dimension as measured by MRI, performed prior to definitive surgery, was compared to the largest pathologic tumor dimension.
  • Histology revealed 20 (80%) invasive ductal carcinomas, 3 (12%) invasive lobular carcinomas, and 2 (8%) mixed lesions.
  • Seven patients underwent reexcision due to positive margins with no further invasive carcinoma identified.
  • CONCLUSION: MRI was effective at estimating invasive breast carcinoma dimension in lesions less than 2 cm.
  • MRI avoided underestimation of pathologic size in small lesions, making it a potentially safe means of identifying the target for minimally invasive techniques.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016726.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Ademuyiwa FO, Thorat M, Nakshatri H, Badve S: Correlation of FOXA1 expression with Oncotype Dx recurrence scores. J Clin Oncol; 2009 May 20;27(15_suppl):11058

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11058 Background: Oncotype Dx assay (ODX) is a diagnostic assay that predicts the benefit of chemotherapy and assesses the likelihood of breast cancer (BC) recurrence in patients with estrogen receptor (ER) positive BC.
  • The forkhead-box A1 (FOXA1) transcription factor is linked to ER regulated gene transcription and its expression is associated with ER positive luminal A type BC.
  • Other variables included age, progesterone receptor (PR) status, tumor size, grade, histological type, and race.
  • Ductal carcinomas accounted for 73.1% of tumors, while 11.5% were lobular.
  • FOXA1 expression correlated negatively with ODX recurrence score (p=.003), and histologic type (p=.024).
  • The correlation between FOXA1 expression and ODX recurrence score remained significant after adjusting for multiple comparisons and controlling for confounders such as histological type, grade, and PR.
  • This observation needs to be confirmed with a larger sample size.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963163.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Gronwald J, Byrski T, Huzarski T, Dent R, Bielicka V, Zuziak D, Wisniowski R, Lubinski J, Narod S: Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.
  • : 502 Background: Neoadjuvant chemotherapy is administered to control disease, make surgical resection possible and increase the possibility of breast tissue conservation.
  • A further advantage of neoadjuvant therapy is that it helps to assess chemo-sensitivity to a particular agent.
  • Induction of a pathological complete response (pCR) is one of the primary goals of neoadjuvant therapy in order to achieve a better disease-free and overall survival.
  • Experimental data suggest that BRCA1 related breast cancer may have increased sensitivity to platinum-based chemotherapy, but clinical data are limited.
  • The aim of this study was to evaluate the frequency of complete pathologic response after neo-adjuvant treatment with cisplatin chemotherapy in women with breast cancer and a BRCA1 mutation.
  • METHODS: Twenty five women with breast cancer and a BRCA1 mutation with stage I, II, and III breast cancer between December 2006 and December 2008 were entered into this study.
  • After chemotherapy, patients underwent surgery and were assessed for pathologic response in both the breast and axillary lymph nodes.
  • Complete pathologic response was defined as no residual invasive disease in both the breast and axilla, however ductal carcinoma in situ was allowed.
  • CONCLUSIONS: Platinum-based chemotherapy is effective in a high proportion of patients with BRCA1-associated breast cancers.
  • Clinical trials are warranted to determine the optimum treatment for this subgroup of breast cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960785.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Le Rhun E, Zairi F, Baranzelli M, Faivre-Pierret M, Devos P, Bonneterre J: Survival of a cohort of 25 breast cancer patients with neoplastic meningitis treated with intrathecal liposomal cytarabine. J Clin Oncol; 2009 May 20;27(15_suppl):1109

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of a cohort of 25 breast cancer patients with neoplastic meningitis treated with intrathecal liposomal cytarabine.
  • : 1109 Background: Neoplastic meningitis (NM) occurs in 5% of the patients with breast cancer; if untreated the median duration of survival is 5 weeks.
  • Combination of intrathecal (IT), systemic chemotherapy, and supportive care may increase overall survival (OS) to 5 months (Chamberlain, 2005).
  • METHODS: 30 consecutive female breast cancer patients diagnosed with NM, on the basis of cerebrospinal fluid (CSF) cytology and/or cerebrospinal MRI with clinical symptoms, have been prospectively treated for 19 months.
  • Three patients did not receive any treatment because of a poor neurological status at diagnosis; 2 patients stopped treatment because of the lack of improvement after 1.5 months.
  • The aim was to report clinico-pathological characteristics and OS in patients treated with IT liposomal cytarabine and supportive care with or without systemic chemotherapy.
  • Breast cancers were invasive ductal carcinoma in 75%.
  • At the time of NM diagnosis CSF cytology and cerebrospinal MRI were positive in respectively 64% and 87.5%.
  • Systemic chemotherapy was given in 56.5% at the discretion of the referring oncologist.
  • A trend was also observed between association with systemic chemotherapy and OS.
  • CONCLUSIONS: Our results confirm that the association of IT, systemic treatment and supportive care treatment may be useful in treating this cancer complication.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962167.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Haid A, Knauer M, Köberle-Wührer R, Wenzl E: Sentinel node biopsy in breast cancer: technique and indication. Wien Klin Wochenschr; 2005 Feb;117(4):121-128

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy in breast cancer: technique and indication.
  • : Sentinel node biopsy (SNB) has proved to be a useful and accurate procedure for lymph node staging in breast cancer and melanoma and should be standard of care in the treatment of these tumors.
  • SNB in breast cancer was accepted as a sole and reliable diagnostic method in breast cancer by the panel of distinguished experts at the 8th international conference of primary therapy of early breast cancer 2003 in St. Gallen.
  • Accepted indications are uni- and multifocal tumors smaller than 3 cm without suspicious findings in the axilla, furthermore SNB is indicated in patients with large ductal carcinoma in situ (>2 cm) and/or with assumed microinvasion.
  • Albeit SNB could be shown to be safe after preoperative chemotherapy and in multicentric breast cancer, due to lack of sufficient data it is still under discussion in these cases.
  • Expedience of this procedure in other lymph node basins, along the mammaria interna vessels or in the infra- and supraclavicular region is considered to be at an investigative stage as well.
  • Detection of additional micrometastases that are found in 10-15% leads to an upgrading from N0 to N1.
  • Broad application and refurbishment led to scientific discussion of prognostic importance of micrometastases and its relevance regarding axillary dissection and adjuvant systemic treatment.
  • Although many unicentric and multicentric observational studies validated by complete axillary dissection could demonstrate that SNB is accurate and suitable for all operable clinically node-negative breast cancers, long-term results and especially the incidence of axillary recurrence and its sequelae are outstanding.
  • Findings of ongoing large prospective randomized trials like NSABP 32, Z0010 and Z0011 of the American College of Surgeons (ACOSOG), the AMAROS-Trial of the European Organisation of Research and Treatment of Cancer (EORTC) and the ALMANAC-Trial of the British Association of Surgical Oncology (BASO) will give a conclusive answer.
  • Significant improvement in morbidity and quality of life measurements could be revealed several times in unicentric and even in multicentric studies like ALMANAC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28108807.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Keywords] NOTNLM ; Breast cancer / Indications / Sentinel node biopsy / Technique
  •  go-up   go-down


31. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, Stevens D, Brain E, Delaloge S, Mathieu M, Guillot E, Vincent-Salomon A, Cottu PH: Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. J Clin Oncol; 2009 May 20;27(15_suppl):517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study.
  • : 517 Background: Trials have shown benefit of adjuvant trastuzumab (TZM) for node-positive (N+) or supra-centrimetric HER-2+ breast carcinomas.
  • There are limited data concerning infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2).
  • METHODS: Retrospective multicenter series from 2000 to 2008 of infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2).
  • Tumors with ≥80% of ductal carcinoma in situ, multifocal and metastatic tumors were excluded.
  • 57% (n = 43) had a sentinel lymph node procedure.
  • 44% (n = 33) had chemotherapy (CT), almost all (31) were associated to TZM.
  • One patient developed myocardial infarction after A resulting in heart failure; 2 had a transient left ventricular ejection fraction decrease below 50% after TZM.
  • Decision of adjuvant CT was associated (all p < 0.05) with hormonal receptors (HR) negative status, Elston-Ellis grade (EE) 2/3 and high mitotic index (MI) while patients with HR+/low MI tumors were rarely treated (p < 0.001).
  • With a 25 months median follow-up, there was no invasive recurrence in TZM treated patients.
  • CONCLUSIONS: In our practice, decision of TZM-based therapy for InfraHER-2 N- tumors is associated with high-risk profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Eralp Y, Basaran G, Dogan M, Dincol D, Demirci S, Icli F, Onur H, Saip P, Topuz E, Haydaroglu A: The outcome of patients with triple negative breast cancer: Evidence for a favorable ethnic subgroup? The Turkish Oncology Group experience. J Clin Oncol; 2009 May 20;27(15_suppl):e22158

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of patients with triple negative breast cancer: Evidence for a favorable ethnic subgroup? The Turkish Oncology Group experience.
  • : e22158 Background: Triple negative breast cancer (TNBC) is generally considered as a poorer prognostic subgroup, with a propensity for earlier relapse and visceral involvement.
  • METHODS: From a retrospective registry cohort of 296 TNBC patients treated and followed between 1993-2007, we identified 248 patients with early stage disease, with follow-up of at least 12 months.
  • The majority of the patient group had invasive ductal carcinoma (n:204, 82.3%).
  • Excluding 11 patients, all had received adjuvant chemotherapy.
  • 5 year overall survival (OS) and disease-free survival (DFS) rates were 84±2.7 % and 69±3.3%, respectively.
  • Univariate analysis revealed locally advanced disease (p:0.0001), larger tumor size (p:0.004), nodal positivity (p<0.00001), and extent of nodal involvement as significant factors for DFS; whereas, locally advanced disease (p:0.0099) and extent of nodal involvement (p:0.018) were identified as prognostic factors with an impact on OS.
  • Multivariate analysis revealed locally advanced disease (HR: 3.3, p:0.02, 95% CI: 0.14-0.64) and extent of nodal involvement (HR:4.3, p:0.033, 95% CI: 0.059-0.88) as significant independent prognostic factors for DFS and OS, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963549.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Meyniel J, Cottu PH, Stern M, Lebigot I, Mignot L, Roman-Roman S, Sastre-Garau X: A genomic and transcriptomic approach to distinguish primary and metastatic ovary tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e22150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22150 Background: Distinction of primary ovarian tumors from metastatic tumors involving the ovary is in some cases challenging for final pathologic diagnosis and for treatment with efficient chemotherapy Methods: We gathered from our biobank 16 pairs of breast/ovarian tumors for some of which the diagnosis was uncertain.
  • The pangenomic profiles of 16 pairs of primary breast carcinoma and ovary tumors (primary tumors or metastases from breast carcinoma) from the same patients were analyzed using the Affymetrix GeneChip Mapping 50K (XbaI) SNP arrays.
  • The data were normalized with GCRMA algorithm and a hierarchical clustering of these samples was performed, together with a dataset of primary and secondary ovary tumors.
  • RESULTS: Primary infiltrating lobular carcinoma (ILC) was observed in 6 patients, infiltrating ductal carcinoma (IDC) in 7 patients, 1 patient had one ILC and one IDC, 1 patient had a mixed IDC+ILC and 1 patient an undifferentiated cancer.
  • All patients received adequate loco-regional and systemic therapies.
  • Median time to diagnosis of ovarian tumor was 54 months.
  • Four patients developed extra-abdominal metastases.
  • Median survival from breast cancer diagnosis was 78 months, and from ovarian tumor diagnosis was 29 months.
  • CONCLUSIONS: We clearly established in this training series that CGH array analysis could help to discriminate between primary and secondary ovarian tumors from breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963541.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Ismael G, Coradazzi AL, Beato CA, Milhomem P, Oliveira J, Manzoni C, Segalla G: Adjuvant systemic therapy in elderly patients with breast cancer: A Brazilian single center experience. J Clin Oncol; 2009 May 20;27(15_suppl):e20711

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant systemic therapy in elderly patients with breast cancer: A Brazilian single center experience.
  • : e20711 Background: Breast cancer is the leading cause of cancer in women in Brazil and in the western world.
  • Despite the high incidence of breast cancer in elderly women, there is no solid information regarding the real impact of the adjuvant systemic therapy in this population, considering the underrepresentation of patients with 65 years of age or older in cancer-treatment trials.
  • Moreover, elderly patients may face some difficulties to receive adequate adjuvant systemic treatment in the routine clinical practice.
  • METHODS: Two hundred fifty eight patients with 65 years of age or older at the time of diagnosis of operable breast cancer and treated in our Institution from February 2000 to December 2005 were retrospectively studied.
  • Clinical and pathological data were recorded as well as the type of adjuvant systemic therapy: hormonal therapy (HT), chemotherapy (CT) or both.
  • We evaluated the disease free survival and overall survival and compared the results between the group of patients treated with HT only and the group of patients treated with both HT and CT.
  • Ductal carcinoma was the most frequent histological type (81%) and grade II were reported in the majority of patients (47.3%).
  • There was no statistical difference between patients treated with HT when compared with the group of patients treat with HT and CT, regarding disease free survival and overall survival.
  • CONCLUSIONS: Despite the age, a considerable part of this elderly breast cancer patient's population has received adjuvant systemic treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961971.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Vigo SA, Sansano M, Marmissolle F, Mainella A, Lujan L, Price P, Antonelli M, Mohamed F, Giacomi N: Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11634

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer.
  • : e11634 Background: Breast cancer (BC) rarely occurs in young women.
  • The original Her2 status was analyzed by immunohistochemistry (IHC) with a polyclonal antibody.
  • All of them were invasive ductal carcinoma.
  • Postoperative radiotherapy was given to 6pts while all pts with Her2/neu positive tumors received chemotherapy with anthracyclines, taxanes and trastuzumab.
  • Disease free survival of 24 month was achieved in 5pts, 1pt died with bone, lung and liver metastases.
  • 2pts had progressive disease (bone and lung metastases one of them, and local recurrence the other one).
  • Progressive disease with distant metastases in bone, lung and liver was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961197.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Lee J, Min W, Kim S, Son B: Comparison of serum HER-2/neu between trastuzumab-based regimen and anthyracycline-based regimen during neoadjuvant chemotherapy in advanced primary breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of serum HER-2/neu between trastuzumab-based regimen and anthyracycline-based regimen during neoadjuvant chemotherapy in advanced primary breast cancer.
  • : e11582 Background: Serum Her-2/neu has been known as molecular surrogating marker of predicting treatment response in Her-2 positive breast cancer.
  • We compare the change of serum Her-2/neu during neoadjuvant chemotherapy between trastuzumab(H) and anthyracyline(A) based treatment.
  • METHODS: All breast cancers were tested by immunohistochemical stain and FISH for Her-2/neu before treatment.
  • Serum Her-2/neu was twice measured by Chemiluminescence immunoassay(ADVIA centaurTMsystem) before neoadjuvant chemotherapy and before operation.
  • Pathologic complete response (pCR) was considered as no residual tumor or remnant ductal carcinoma in situ, partial response (PR) was less than 50% decrease in maximal diameter in pathologic tumor size.
  • CONCLUSIONS: A decrease in serum Her-2/neu levels during treatment was associated with pathologic response in patients receiving neoadjuvant chemotherapy, particularly, trastuzumab-based regimen.
  • Serum Her-2/neu levels may serve to monitoring neoadjuvant therapy in Her-2/neu positive breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964116.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Tse GM, Yeung DK, King AD, Cheung HS, Yang WT: In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res Treat; 2007 Sep;104(3):249-55
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo proton magnetic resonance spectroscopy of breast lesions: an update.
  • In vivo proton magnetic resonance spectroscopy ((1)H-MRS) has been demonstrated to be successful in the differentiation of benign and malignant breast lesions in a non-invasive manner by detecting increased levels of composite choline (Cho) compounds.
  • Currently there is molecular evidence of increased Cho metabolism in breast cancer cells.
  • In breast malignancies, (1)H-MRS achieved a high-overall sensitivity (82%).
  • Most test cases were infiltrating duct carcinoma, but infiltrating lobular, medullary, mucinous and adenoid cystic carcinomas were also positive by (1)H-MRS.
  • Another potential of (1)H-MRS is to assess patients' response to neoadjuvant chemotherapy.
  • In ductal carcinoma in situ, the results of (1)H-MRS on the limited number of cases were negative.
  • Most of the assessed benign breast lesions including fibroadenoma, fibrocystic changes, cysts and galactoceles, papilloma, tubular adenoma and phyllodes tumours and were mostly negative by (1)H-MRS, with an overall false positive rate was about 8%.
  • Normal breast tissue was almost always negative by (1)H-MRS, whereas, lactating breast tissue showed positivity with a slightly different spectrum on further analysis.
  • With these improvements, (1)H-MRS may potentially be useful in detection of smaller malignant lesions, characterization of malignant lesions into non-invasive or invasive, and as an invaluable tool in disease progression monitoring.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Breast / pathology. Carcinoma / metabolism. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Choline / metabolism. Disease Progression. False Positive Reactions. Female. Humans. Protons. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051424.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protons; N91BDP6H0X / Choline
  • [Number-of-references] 36
  •  go-up   go-down


38. Wang X, Yuan S, Wang J, Lin P, Liu G, Lu Y, Zhang J, Wang W, Wei Y: Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo. Toxicol Appl Pharmacol; 2006 Sep 1;215(2):168-78
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.
  • The purpose of this study is to confirm the anticancer activity of LFP extract on human breast cancer in vitro and in vivo, and to elucidate the mechanism of its activity.
  • Human breast cancer cells were tested in vitro for cytotoxicity, colony formation inhibition, BrdU incorporation, and gene expression profiling after treatment with LFP extract.
  • Seven nude mice bearing human breast infiltrating duct carcinoma orthotopically were tested for its anticancer activity and expression of caspase-3 in vivo by oral administration of 0.3% (0.3 mg/ml) of LFP water-soluble crude ethanolic extract (CEE) for 10 weeks.
  • LFP extract demonstrated a dose- and time-dependent inhibitory effect on cell growth (IC(50) = 80 microg/ml), and it significantly inhibited colony formation and BrdU incorporation of human breast cancer cells.
  • Oligonucleotide microarray analysis identified 41(1.22%) up-regulated and 129 (3.84%) down-regulated genes after LFP water-soluble CEE treatment; the predominantly up-regulated genes were involved in various biological functions including cell cycle regulation and cell proliferation, apoptosis, signal transduction and transcriptional regulation, and extracellular matrix/adhesion molecules; and down-regulated genes were mainly associated with adhesion, invasion, and malignancy of cancer cells.
  • The findings in this study suggested that LFP extract might have potential anticancer activity on both ER positive and negative breast cancers, which could be attributed, in part, to its DNA damage effect, proliferating inhibition and apoptosis induction of cancer cells through up-regulation and down-regulation of multiple genes involved in cell cycle regulation and cell proliferation, apoptosis, signal transduction and transcriptional regulation, motility and invasiveness of cancer cells; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)-like 1 (ADPRTL1), Cytochrome P450, subfamily I (CYP1A1) and Hyaluronan-mediated motility receptor (HMMR) might be the main molecular targets at which LFP water-soluble CEE acted.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Litchi. Phytotherapy. Plant Extracts / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Fruit / chemistry. Gene Expression / drug effects. Gene Expression Profiling. Humans. Mice. Mice, Nude. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Oligonucleotide Array Sequence Analysis. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563451.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Neoplasm Proteins; 0 / Plant Extracts
  •  go-up   go-down


39. Capitain O, Lortholary A, Abadie-Lacourtoisie S: [Cytolytic hepatitis and esomeprazole during chemotherapy]. Presse Med; 2005 Oct 08;34(17):1235-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytolytic hepatitis and esomeprazole during chemotherapy].
  • INTRODUCTION: Esomeprazole, the pure S isomer form of omeprazole, is indicated for the treatment of peptic esophagitis.
  • CASE: A 41-year-old woman with infiltrating ductal carcinoma of the breast was undergoing chemotherapy with paclitaxel and trastuzumab.
  • These tests returned to normal levels despite continuation of the chemotherapy.
  • DISCUSSION: This cytolytic hepatitis is very probably imputable to esomeprazole, but a synergistic hepatic toxicity of the chemotherapy with esomeprazole cannot be ruled out.
  • [MeSH-major] Anti-Ulcer Agents / adverse effects. Anti-Ulcer Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Chemical and Drug Induced Liver Injury / pathology. Esomeprazole / adverse effects. Esomeprazole / therapeutic use
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagitis / chemically induced. Esophagitis / drug therapy. Female. Humans. Paclitaxel / administration & dosage. Trastuzumab

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230965.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; N3PA6559FT / Esomeprazole; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


40. Plunkett TA, Hanby AM, Miles DW, Rubens RD: Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy. Ann Oncol; 2001 Mar;12(3):411-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy.
  • BACKGROUND: Eccrine porocarcinoma is an uncommon neoplasm of the intra-epidermal sweat gland duct.
  • PATIENTS AND METHODS: A case of eccrine porocarcinoma in a female renal transplant patient aged 45 years is described with a review of pertinent literature.
  • In places large and small cells merged and focally the former component infiltrated the epidermis in a manner akin to Paget's disease of the breast.
  • The majority of the tumour was high grade; using the modified Bloom and Richardson grading system, usually applied to mammary ductal carcinomas, the tumour graded as 3.
  • Metastatic disease developed nine months following primary surgical treatment.
  • The metastatic eccrine porocarcinoma was resistant to epirubicin but responded to docetaxel chemotherapy.
  • CONCLUSIONS: There are no data to support the use of adjuvant therapy in the management of eccrine porocarcinoma.
  • The use of the modified Bloom and Richardson grading system may define cases at high risk of relapse in which adjuvant therapy might be considered.
  • We report the first use of docetaxel in the management of this disease.
  • The treatment was well tolerated and resulted in marked symptomatic and radiological responses.
  • Treatment with docetaxel should be considered in future cases of this rare tumour.

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11332156.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


41. Sullivan PS, Apple SK: Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? Breast J; 2009 Mar-Apr;15(2):146-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
  • Neoadjuvant chemotherapy is becoming the standard of care in locally advanced breast cancers.
  • We retrospectively identified 49 cases of invasive breast carcinoma treated with neoadjuvant chemotherapy (40 ductal, nine lobular) and examined histologic and biologic features of ductal and lobular carcinoma before and after chemotherapy.
  • Patients with lobular carcinomas presented at a later age and had lower grade tumors that were more likely estrogen and progesterone receptor positive.
  • Ductal carcinomas had a greater frequency of HER-2/neu amplification and increased Ki-67 rate.
  • After chemotherapy, none of the lobular carcinomas had complete pathologic response compared with 28% of the ductal carcinomas (p = 0.01).
  • Lobular carcinomas had more lymph node metastases.
  • At the time of clinical follow-up, no lobular carcinomas had evidence of disease.
  • Only one lobular carcinoma case had any histologic changes after chemotherapy compared with 37-68% of ductal carcinomas (p < 0.05).
  • In ductal carcinomas, higher grade and negative estrogen receptor expression before chemotherapy and presence of foam cell clusters, HER-2/neu expression, and absence of lymphatic or vascular space invasion after chemotherapy correlated with pathologic response (p < 0.05).
  • Decreased Ki-67 rate after chemotherapy correlated with survival (p = 0.024).
  • Breast biomarker status changed in 9% of all lobular carcinomas and 19% of all ductal carcinomas.
  • Lobular carcinomas respond poorly to neoadjuvant chemotherapy as evidence by lack of complete pathologic response and rare histologic tissue response.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Chemotherapy, Adjuvant / methods
  • [MeSH-minor] Adult. Aged. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Invasiveness. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. Tumor Suppressor Protein p53 / analysis


42. Bagrodia A, Gold R, Handorf C, Liman A, Derweesh IH: Salvage paclitaxel chemotherapy for metastatic collecting duct carcinoma of the kidney. Can J Urol; 2008 Dec;15(6):4425-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage paclitaxel chemotherapy for metastatic collecting duct carcinoma of the kidney.
  • We report a case of metastatic collecting duct carcinoma (CDC) incidentally found on computer assisted tomography in an 18-year-old male who presented status post a motor vehicle crash (MVC).
  • The patient underwent total nephrectomy/renal vein thrombectomy with retroperitoneal lymph node dissection, followed by multimodal therapy, with gemcitabine and platinum salt therapy, effecting a short lived complete response, followed by single agent paclitaxel chemotherapy effecting a similarly short lived partial response.
  • We conclude that cytoreductive nephrectomy and lymphadenectomy combined with chemotherapy may be useful for extending and increasing the quality of life of selected patients with CDC.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Paclitaxel / therapeutic use. Salvage Therapy
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Humans. Male

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046497.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel
  •  go-up   go-down


43. Murakami K, Sakata H, Miyazawa Y, Matsushita K, Akutsu Y, Nishimori T, Yoneyama Y, Usui A, Kano M, Matsubara H, Ochiai T: [Two cases treated with trastuzumab as primary chemotherapy]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1683-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases treated with trastuzumab as primary chemotherapy].
  • We report two cases treated with primary chemotherapy containing trastuzumab with a review of some important papers.
  • A 33-mm left breast invasive ductal carcinoma (ER (-), PgR (-), HER2 3+(IHC) ) with several lymph node metastases in the Ax, Ic and Sc was found.
  • After primary chemotherapy with 6 courses of EC and 4 courses of weekly paclitaxel + trastuzumab, the efficacy for the local tumor was judged as PR.
  • Brain metastases were then treated by gamma-knife three times, but systemic chemotherapy was not administered.
  • Intrathecal chemotherapy with MTX+Ara-C was started, but the patient died after 20 months from the beginning of the treatment.
  • A 39-mm right breast invasive ductal carcinoma (ER (-), PgR (-), HER2 3+(IHC) ) with two lymph node metastases in the Ax was found.
  • After primary chemotherapy with 6 courses of FEC and 4 courses of weekly paclitaxel + trastuzumab, the efficacy was judged as PR.
  • The operation was scheduled, but he patient wished to continue chemotherapy for cosmetic reasons.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Female. Humans. Paclitaxel / administration & dosage. Trastuzumab

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940391.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


44. Hatami M, Whitney K, Goldberg GL: Primary bilateral ovarian and uterine Burkitt's lymphoma following chemotherapy for breast cancer. Arch Gynecol Obstet; 2010 Apr;281(4):697-702
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bilateral ovarian and uterine Burkitt's lymphoma following chemotherapy for breast cancer.
  • A case of Burkitt's lymphoma involving the uterus, cervix, ovaries and appendix 15 years after adjuvant chemotherapy for breast cancer is presented.
  • Her past medical history was significant for an infiltrating ductal carcinoma of the left breast with positive lymph nodes and extra nodal invasion diagnosed at age 43.
  • She had a left modified radical mastectomy in 1990 with adjuvant chemotherapy.
  • After complete staging, chemotherapy was started and the patient is presently tumor free 41 months after the diagnosis.
  • Early diagnosis, aggressive chemotherapy, +/-surgical intervention, plays an important role in management and survival of patients with Burkitt's lymphoma.
  • [MeSH-major] Appendix / pathology. Breast Neoplasms / drug therapy. Burkitt Lymphoma / pathology. Carcinoma, Ductal, Breast / drug therapy. Neoplasms, Second Primary / pathology. Ovary / pathology. Uterus / pathology


45. Katz A, Saad ED, Porter P, Pusztai L: Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol; 2007 Jan;8(1):55-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic chemotherapy of invasive lobular carcinoma of the breast.
  • Invasive lobular carcinoma is the second most frequent histological type of breast cancer and its incidence is increasing.
  • Invasive lobular carcinoma is almost invariably positive for the oestrogen receptor and, when compared with invasive ductal carcinoma, it is typically of a lower grade.
  • Even though invasive lobular carcinoma represents a distinct clinical entity, the same criteria used for invasive ductal carcinoma are currently applied to establish the need for primary or adjuvant systemic chemotherapy.
  • We reviewed randomised trials of neoadjuvant and adjuvant chemotherapy and noted that insufficient evidence is available to support or withhold use of chemotherapy in patients with invasive lobular carcinoma.
  • Thus, the benefit from systemic chemotherapy for individuals with this form of breast disease is unclear.
  • Invasive lobular carcinoma deserves to be investigated separately in prospective clinical trials to define the best treatment and prevention strategies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Lobular / drug therapy. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials as Topic. Female. Humans. Incidence

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196511.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 75
  •  go-up   go-down


46. Yin HF, Wang YH, Qin XQ, Zhang H, Li T, Ye JM, Liu YH: [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Nov;31(11):858-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
  • OBJECTIVE: The aim of this study is to investigate the changes of expression of estrogen receptors (ER), progesterone receptors (PR), Her-2, Ki-67 and histological grade after neoadjuvant chemotherapy in breast cancer.
  • METHODS: Sixty-seven patients with histopathalogically confirmed breast cancer by core needle biopsy received neoadjuvant chemotherapy.
  • The effect of neoadjuvant chemotherapy was assessed according to the criteria of the Japanese Breast Cancer Society: non-effective (G1), mildly effective (G2), moderately effective (G3), markedly effective (G4) and completely effective (G5).
  • The pre- and post-neoadjuvant chemotherapy status of tumor histological grade, ER and PR, Her-2 and Ki-67 expression in the 49 cases were compared.
  • RESULTS: The effect of neoadjuvant chemotherapy was assessed in 67 patients.
  • PR positive rate was 71.4% after chemotherapy versus 91.8% before chemotherapy, with a statistically significant reduction (P = 0.021).
  • However, the ER and Her-2 expression before and after neoadjuvant chemotherapy was stable.
  • Of the patients with invasive ductal carcinoma, 28.6% had histological grade change after neoadjuvant chemotherapy, and 85.7% of patients decreased one grade.
  • The average rate of Ki-67 expression decreased from 28.3% pre-chemotherapy to 11.0% post-chemotherapy (P = 0.011).
  • After the neoadjuvant chemotherapy, the Ki-67 expression rate decreased by > 10%, > 20%, > 30%, > 40% and > 50% in 3 groups (G1 and G2, group G3, group G4 and G5) showed a tendency to be increased, with a significant difference (P < 0.05).
  • CONCLUSION: PR expression in breast cancer decreases after neoadjuvant chemotherapy, while ER and Her-2 expressions remain stable.
  • After neoadjuvant chemotherapy, the histological grade and proliferation index are decreased and correlated with the response to chemotherapy.
  • Therefore, histological grade and proliferation index may be effective complementary factors in assessment of the effectiveness of neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Breast Neoplasms. Carcinoma, Ductal, Breast. Neoadjuvant Therapy / methods
  • [MeSH-minor] Adult. Aged. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Epirubicin / administration & dosage. Female. Humans. Ki-67 Antigen / metabolism. Middle Aged. Paclitaxel / administration & dosage. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Retrospective Studies. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137353.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; EC 2.7.10.1 / Receptor, ErbB-2; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


47. Brunner TB, Eccles CL: Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol; 2010 Dec;186(12):672-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.
  • PURPOSE: this report aims to provide an overview on radiotherapy and chemotherapy in extrahepatic biliary duct carcinoma (BDC).
  • RESULTS: most patients with cholangiocarcinoma present with unresectable disease (80-90%), and more than half of the resected patients relapse within 1 year.
  • Adjuvant and palliative treatment options need to be chosen carefully since 50% of the patients are older than 70 years at diagnosis.
  • Adjuvant radiotherapy or chemotherapy after complete resection (R0) has not convincingly shown a prolongation of survival but radiotherapy did after R1 resection.
  • However, data suggest that liver transplantation could offer long-term survival in selected patients when combined with neoadjuvant chemoradiotherapy in patients with marginally resectable disease.
  • For patients with unresectable biliary tract carcinoma (BTC), palliative stenting was previously the treatment of choice.
  • Progress is less pronounced in chemotherapy.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / radiotherapy. Bile Ducts, Extrahepatic. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / radiotherapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Liver Transplantation. Neoadjuvant Therapy. Palliative Care. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant. Radiotherapy, Intensity-Modulated. Randomized Controlled Trials as Topic. SEER Program. Stents. Survival Analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2010 Apr 8;362(14):1273-81 [20375404.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):788-97; discussion 797-8 [7794082.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):189-95 [16542787.001]
  • [Cites] Hepatogastroenterology. 2004 Jul-Aug;51(58):954-7 [15239222.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):201-7 [15192792.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2210-8 [10829040.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72 (2):582-8 [18793961.001]
  • [Cites] Ann Surg. 1994 Mar;219(3):267-74 [8147607.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):969-74 [12095564.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1689-700 [14534886.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):125-31 [1312319.001]
  • [Cites] Lancet. 1992 Dec 19-26;340(8834-8835):1488-92 [1281903.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):657-64 [18172187.001]
  • [Cites] Am J Surg. 1997 Dec;174(6):605-8; discussion 608-9 [9409582.001]
  • [Cites] World J Surg. 2003 Feb;27(2):173-9 [12616432.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1612-8 [15532789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1087-92 [9392548.001]
  • [Cites] Gastrointest Endosc. 2003 Feb;57(2):178-82 [12556780.001]
  • [Cites] Hepatogastroenterology. 2008 Nov-Dec;55(88):1951-4 [19260456.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):183-6 [11300321.001]
  • [Cites] World J Surg. 1988 Feb;12(1):91-8 [2830731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1357-65 [14630274.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1402-7 [15726542.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Strahlenther Onkol. 2008 Jan;184(1):8-14 [18188517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):178-82 [17276614.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):653-6 [9681080.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):571-8 [15890602.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):790-6 [16716757.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):581-7 [10701737.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):425-8 [10955877.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):414-9 [12243816.001]
  • [Cites] Gut. 1996 Dec;39(6):852-5 [9038668.001]
  • [Cites] Radiother Oncol. 2009 Aug;92(2):249-54 [19324442.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1495-501 [18472359.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):929-35 [9369143.001]
  • [Cites] Am J Surg. 1990 Jan;159(1):91-7; discussion 97-8 [1688486.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):702-4 [12232749.001]
  • [Cites] Hepatogastroenterology. 1995 Jul;42(3):265-8 [7590576.001]
  • [Cites] J Clin Oncol. 1996 Aug;14 (8):2311-5 [8708722.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):848-58 [17012047.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6):786-94 [11084070.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):483-8 [16242254.001]
  • [Cites] Am Surg. 2001 Sep;67(9):839-43; discussion 843-4 [11565760.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1191-8 [19201549.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Oct;31(11):1835-7 [15553731.001]
  • [Cites] Strahlenther Onkol. 2009 Nov;185(11):736-42 [19899007.001]
  • [Cites] Cancer J. 2002 Jan-Feb;8(1):74-8 [11895206.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):148-53 [18805651.001]
  • [Cites] Br J Surg. 1995 Nov;82(11):1522-5 [8535808.001]
  • [Cites] Gastrointest Endosc. 2006 Jun;63(7):986-95 [16733114.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):883-94 [73534.001]
  • [Cites] Strahlenther Onkol. 2004 Dec;180(12):751-7 [15592694.001]
  • [Cites] Med Phys. 1997 Jan;24(1):103-10 [9029544.001]
  • [Cites] Cancer. 2009 Nov 15;115(22):5175-83 [19637356.001]
  • [Cites] Acta Oncol. 2006;45(7):856-64 [16982550.001]
  • [Cites] Strahlenther Onkol. 2009 Nov;185(11):715-21 [19899003.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Jan;18(1):63-7 [2153649.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Radiother Oncol. 2010 Jan;94(1):47-52 [19963295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):945-51 [8138448.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):331-8 [3104245.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):810-21 [12095546.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1973 Jan;117(1):73-80 [4685535.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):855-61 [8040034.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Endoscopy. 2006 Aug;38(8):787-92 [17001568.001]
  • [Cites] Strahlenther Onkol. 2008 Dec;184(12 ):663-7 [19107347.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):61-6 [8961369.001]
  • [Cites] Am J Surg. 1991 Apr;161(4):454-8 [1709795.001]
  • (PMID = 21136029.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0700730
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  •  go-up   go-down


48. Soucy G, Bélanger J, Leblanc G, Sideris L, Drolet P, Mitchell A, Leclerc YE, Dufresne MP, Beaudet J, Dubé P: Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact? J Am Coll Surg; 2008 Jun;206(6):1116-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact?
  • BACKGROUND: Regression of breast tumors in response to neoadjuvant chemotherapy is variable.
  • The goal of breast-conservation operation after neoadjuvant chemotherapy is generally to resect any residual tumor with negative margins.
  • The purpose of this study was to compare surgical margin involvement of breast-conservation resection specimens from patients treated initially with operation with those from patients receiving neoadjuvant chemotherapy.
  • METHODS: Between January 2003 and June 2006, 478 breast-conservation operations were performed for invasive breast cancer at our institution.
  • Seventy-six patients received neoadjuvant chemotherapy.
  • Data collected included age, tumor size, nodal status, hormonal receptors and Her-2-neu status, lymphovascular invasion, histologic grade and type, use of guidewire, preoperative chemotherapy regimens, and microscopic evaluation of surgical margins.
  • RESULTS: No statistical difference was observed for margin involvement between patients treated with neoadjuvant chemotherapy and those treated initially with operation (21% versus 18%; p = 0.52).
  • Variables associated with positive margins in a logistic regression model were carcinoma type (43% of all lobular carcinomas had positive margins versus 16% in ductal carcinomas; p = 0.002) and hormonal receptor status (margin involvement was present in 20% of tumors that exhibited hormonal receptors versus 10% in negative receptors tumors; p = 0.014).
  • CONCLUSIONS: Breast conservation after neoadjuvant systemic therapy yields no higher incidence of positive margins than primary surgical treatment.
  • Special consideration should be accorded to lobular carcinoma, because our findings, consistent with previous studies, demonstrate an association with margin involvement.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / surgery. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / surgery. Mastectomy, Segmental
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Logistic Models. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501808.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


49. Konishi K, Hasegawa N, Kaneko H, Iimura Y, Shoji Y, Kawabata M: [Two cases of breast cancer responding to primary systemic chemotherapy containing trastuzumab without surgery]. Gan To Kagaku Ryoho; 2010 Jan;37(1):115-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of breast cancer responding to primary systemic chemotherapy containing trastuzumab without surgery].
  • The first case was a 40-year-old woman who was referred to our hospital with a complaint of left breast tumor.
  • She was diagnosed as invasive ductal carcinoma (T2N0M0, Stage IIA).
  • After primary systemic chemotherapy with 6 courses of 5-fluorouracil+epirubicin+cyclophosphamide(FEC)and 3 courses of weekly paclitaxel (PTX)+trastuzumab, the efficacy of chemotherapy was judged as a complete response (CR).
  • After chemotherapy, radiotherapy for her left breast was performed without surgery.
  • The efficacy of chemotherapy was judged as a partial response (PR).
  • The second case was a 26-year-old woman referred to our hospital with a complaint of right breast tumor.
  • She was diagnosed as invasive lobular carcinoma (T2N0M0, Stage IIA).
  • After primary systemic chemotherapy with 4 courses of FEC and 6 courses of docetaxel+trastuzumab, the efficacy of chemotherapy was judged as CR.
  • After chemotherapy, radiotherapy for her right breast was performed without surgery.
  • The efficacy of treatment was judged as CR for 15 months.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Combined Modality Therapy. Female. Humans. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087043.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; P188ANX8CK / Trastuzumab
  •  go-up   go-down


50. Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Lucci A, Hunt KK, Bedrosian I: Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol; 2009 Jun;16(6):1606-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.
  • BACKGROUND: Patients with invasive lobular carcinoma (ILC) experience a lower pathological complete response rate to neoadjuvant chemotherapy than patients with invasive ductal carcinoma.
  • This study was intended to evaluate the impact of neoadjuvant chemotherapy in ILC on breast-conserving surgery (BCS) rates.
  • Surgical procedures and long-term outcomes were compared between patients receiving neoadjuvant chemotherapy and those receiving surgery first.
  • RESULTS: Neoadjuvant chemotherapy was administered to 84 patients; 200 patients underwent surgery first.
  • When controlled for initial tumor size, there was no difference (all p > 0.05) between the groups in terms of (1) the proportion of patients who underwent an initial attempt at BCS, (2) rate of failure of BCS or (3) the proportion of patients undergoing BCS as their final procedure.
  • With a mean follow-up of 47 months, local recurrence (LR) rates were similar between the two groups (1.2% versus 0.5%, p = 0.5).
  • CONCLUSION: The use of neoadjuvant chemotherapy does not increase the rates of breast conservation in patients with pure ILC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Lobular / drug therapy. Mastectomy, Segmental / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Mastectomy / statistics & numerical data. Middle Aged. Neoadjuvant Therapy. Retrospective Studies

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280264.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS660874; NLM/ PMC4338983
  •  go-up   go-down


51. Horii R, Akiyama F, Ito Y, Matsuura M, Miki Y, Iwase T: Histological features of breast cancer, highly sensitive to chemotherapy. Breast Cancer; 2007;14(4):393-400
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological features of breast cancer, highly sensitive to chemotherapy.
  • BACKGROUND: To establish tailor-made therapy for breast cancer, we investigated the possibility of predicting chemotherapy sensitive cases based on pre-therapeutic histological features.
  • METHODS: A total of 87 breast cancer patients underwent neoadjuvant chemotherapy with a paclitaxel (80 mg/m(2)/q1w, 12 courses)or an epirubicin regimen (90 mg/m(2)/q3wks, 4 courses).
  • We investigated the chemo-sensitivity of invasive ductal carcinoma, solid-tubular carcinoma consisting of highly malignant cancer cells with many mitoses.
  • We refer to this type of carcinoma as " chemo-sensitive carcinoma " and compared the histological therapeutic effects of chemo-sensitive and chemo-insensitive carcinomas. RESULTS:.
  • 1) Out of 87 patients, 20 cases (23%) showed the histological features of chemo-sensitive carcinomas on pre-therapeutic needle biopsy specimens.
  • The remaining 67 cases (77%) were classified as chemo-insensitive carcinoma.
  • 2) Histologically marked or complete response were observed in 50% (10/20) of chemo-sensitive carcinomas and 10% (7/67) of chemo-insensitive carcinomas (chi(2)=15.33, p=0.0001).
  • Multivariate analysis of chemo-sensitive carcinoma, including HER2, hormone receptor and p53 status, revealed that chemo-sensitive carcinoma had a significant correlation with the histological therapeutic effects (p=0.01119).
  • 3) Pathological complete response (pCR) was achieved in 35% (7/20) of chemo-sensitive carcinomas and 1.5% (1/67)of chemo-insensitive carcinomas (chi(2)=20.71, p<0.0001).
  • Multivariate analysis revealed that chemo-sensitive carcinoma had a significant correlation with pCR (p=0.0091).
  • CONCLUSION: The histological features of chemo-sensitive carcinoma were significant predictive factors for chemotherapeutic efficacy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / drug therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Epirubicin / administration & dosage. Female. Humans. Middle Aged. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986805.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


52. Todoroki T: Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology; 2000 May-Jun;47(33):644-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery.
  • Chemotherapeutic regimens that markedly improve survival and quality of life in patients with bile duct cancer (cholangiocarcinoma) have not yet been developed.
  • Currently, radical resection is the only potentially curative treatment modality for these patients.
  • During the past 25 years, patients with cholangiocarcinoma have received chemotherapy in an attempt to improve their prognosis; effective methods are systemic administration, hepatic arterial infusion, and intraductal infusion.
  • In particular, 5-fluorouracil has been a component of most chemotherapy regimens for bile duct cancer.
  • Hepatic arterial infusion chemotherapy was associated with the highest response rate and survival in patients with localized cholangiocarcinoma (localized in the liver, with no extra-hepatic metastasis); however, these results need to be confirmed in large, randomized trials.
  • Studies regarding intraductal chemotherapy for patients with obstructive jaundice are still in the preliminary stages; therefore, no associated benefit could be ascertained.
  • The present review discusses current chemotherapy regimens for bile duct cancer and outlines possible future clinical investigations.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Infusions, Intra-Arterial

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for bile duct carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10919004.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 54
  •  go-up   go-down


53. Vénat-Bouvet L, Desfougères M, Aubard Y, Mollard J, Fermeaux V, Genet D, Labourey JL, Martin J, Lebrun-Ly V, Maubon A, Tubiana-Mathieu N: [MRI evaluation of primary chemotherapy response in breast cancer]. Bull Cancer; 2004 Sep;91(9):721-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MRI evaluation of primary chemotherapy response in breast cancer].
  • [Transliterated title] Evaluation par IRM de la réponse à la chimiothérapie d'induction dans les cancers du sein.
  • The aim of this work was to evaluate the value of contrast enhanced MRI for determination of response to neoadjuvant chemotherapy (type FEC) in breast cancer according to two parameters: size of the enhancing tumor and the maximum relative enhancement curve (MRC) in the same tumor area.
  • Twenty women with breast cancer (15 invasive ductal carcinomas and 5 invasive lobular carcinomas) T2 (n = 8) or T3 (n = 12) were evaluated by physical examination and MRI after a minimal of three courses of FEC and prior to surgery.
  • A MRC flattening was observed in 5 cases among the patients with a partial response or clinical stable disease correlated with a poor cellular density in the microscopic findings.
  • MRI monitoring of chemotherapy response can be useful for guiding surgery.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy. Magnetic Resonance Imaging
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Neoplasm, Residual

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15544998.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


54. Rudas M, Filipits M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R, Pohl G: Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat; 2003 Sep;81(2):149-57
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy.
  • Our purpose was to determine the expression of the drug resistance factors multidrug resistance protein (MRP1), lung resistance protein (LRP) and P-glycoprotein (Pgp) in breast carcinoma patients treated with preoperative chemotherapy.
  • We have studied the expression of these proteins in breast carcinomas by immunohistochemistry both prior (n = 80) and after (n = 68) preoperative chemotherapy and compared their expression with response to preoperative chemotherapy.
  • In paired samples prior and after chemotherapy expression of drug resistance factors was significantly lower in prechemotherapy samples as compared with postchemotherapy specimens.
  • Pgp expression was more frequently detected in lobular carcinomas than in ductal carcinomas (93% vs. 46%, P = 0.001) and in patients with positive lymph nodes than in patients with negative lymph nodes (65% vs. 31%, P = 0.008) but was independent of other clinical parameters.
  • No significant associations were found between the prechemotherapy or postchemotherapy expression of either of these three proteins and response to preoperative chemotherapy.
  • In conclusion, preoperative chemotherapy increases the expression of MRP1, LRP and Pgp.
  • Response to chemotherapy is not associated with pre- or postchemotherapy expression levels of these drug resistance proteins but time to progression may be influenced by prechemotherapy MRP1 expression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Multidrug Resistance-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Drug Resistance, Multiple / drug effects. Drug Resistance, Neoplasm / drug effects. Female. Humans. Immunohistochemistry. Middle Aged. Neoadjuvant Therapy. Proportional Hazards Models. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14572157.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


55. Bogoevski D, Chayeb H, Cataldegirmen G, Schurr PG, Kaifi JT, Mann O, Yekebas EF, Izbicki JR: Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy. J Gastrointest Surg; 2008 Nov;12(11):1830-7; discussion 1837-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy.
  • BACKGROUND: To assess the prognostic significance of nodal microinvolvement in patients with carcinoma of the papilla of Vater.
  • METHODS: From 1993 to 2003 at the University Clinic Hamburg, 777 patients were operated upon pancreatic and periampullary carcinomas.
  • The vast majority of patients were operated upon pancreatic ductal adenocarcinoma (n = 566, 73%), followed by carcinomas of the papilla of Vater (n = 112, 14%), pancreatic neuroendocrine carcinomas (n = 39, 5%), intraductal papillary mucinous neoplasms (n = 33, 4%), and distal bile duct carcinomas (n = 27, 3%).
  • Fresh-frozen tissue sections from 169 lymph nodes (LNs) classified as tumor free by routine histopathology from 57 patients with R0 resected carcinoma of the papilla of Vater who had been spared from adjuvant chemotherapy were immunohistochemically (IHC) examined, using a sensitive IHC assay with the anti-epithelial monoclonal antibody Ber-EP4 for tumor cell detection.
  • CONCLUSIONS: The influence of occult tumor cell dissemination in LNs of patients with histologically proven carcinoma of the papilla of Vater supports the need for further tumor staging through immunohistochemistry.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / surgery. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Chemotherapy, Adjuvant. Cohort Studies. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 1989 Jan;21(1):11-5 [2474791.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):101-8 [8382467.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Scand J Gastroenterol. 1999 Aug;34(8):808-12 [10499482.001]
  • [Cites] Eur J Surg Oncol. 1987 Oct;13(5):409-11 [3311817.001]
  • [Cites] J Hematother. 1994 Fall;3(3):165-73 [7530132.001]
  • [Cites] Lifetime Data Anal. 1995;1(2):195-204 [9385101.001]
  • [Cites] Ann N Y Acad Sci. 1993 Aug 12;690:42-9 [8368769.001]
  • [Cites] HPB (Oxford). 2007;9(2):135-9 [18333129.001]
  • [Cites] Eur J Surg. 1996 Dec;162(12):961-7 [9001878.001]
  • [Cites] J Clin Pathol. 1981 Jul;34(7):779-84 [7021603.001]
  • [Cites] Immunol Today. 1997 Feb;18(2):89-95 [9057360.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1039-46 [10421536.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):928-33 [12845952.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):410-4 [1617591.001]
  • [Cites] Chirurg. 2000 Feb;71(2):196-201 [10734589.001]
  • [Cites] Ann Chir. 2006 May;131(5):322-7 [16615931.001]
  • [Cites] Ann Surg. 1983 Sep;198(3):386-97 [6615059.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):945-53 [10863064.001]
  • [Cites] Surgery. 2001 May;129(5):537-46 [11331445.001]
  • [Cites] Pathologe. 2003 May;24(3):196-203 [12739053.001]
  • [Cites] World J Gastroenterol. 2006 Oct 28;12(40):6515-21 [17072983.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1827-32 [8083707.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):993-1000; discussion 1000-1 [15570205.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2883-91 [3552208.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6836-40 [11156375.001]
  • [Cites] J Clin Pathol. 1990 Mar;43(3):213-9 [1692040.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):448-56 [15170447.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1027-31 [7679945.001]
  • [Cites] Br J Cancer. 1986 Oct;54(4):631-6 [3535864.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):664-8 [4053908.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 17;85(6):493-8 [7680382.001]
  • [Cites] World J Surg Oncol. 2006 Mar 08;4:14 [16524478.001]
  • [Cites] Am J Surg. 1996 Nov;172(5):463-8; discussion 468-9 [8942545.001]
  • [Cites] Ann Thorac Surg. 1994 Nov;58(5):1569-70 [7979715.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Feb;23(2):137-47 [2450753.001]
  • [Cites] Z Gastroenterol. 1998 May;36(5):479-81 [9654711.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Lancet. 1990 Jun 30;335(8705):1565-8 [1972494.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):523-7 [1520589.001]
  • [Cites] Science. 1977 Aug 26;197(4306):893-5 [887927.001]
  • (PMID = 18791769.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Kaufmann P, Dauphine CE, Vargas MP, Burla ML, Isaac NM, Gonzalez KD, Rosing D, Vargas HI: Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery. Am Surg; 2006 Oct;72(10):935-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery.
  • Neoadjuvant chemotherapy (NC) in patients with breast cancer results in high response rates and has been used with the purpose of reducing tumor size and achieving breast conservation (BC) in individuals who initially require mastectomy.
  • We conducted a cohort study of women with invasive breast cancer who required mastectomy but desired BC surgery.
  • Tumors were predominantly infiltrating ductal carcinoma (83.3%) and high grade (62.2%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Mastectomy. Mastectomy, Segmental. Neoadjuvant Therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Biomarkers, Tumor / analysis. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma / surgery. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Cohort Studies. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Remission Induction. Retrospective Studies. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058739.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


57. Bini A, Zompatori M, Ansaloni L, Grazia M, Stella F, Bazzocchi R: Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case. Surg Today; 2000;30(5):469-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case.
  • Secondary spontaneous pneumothorax (SSP) is a rare complication of chemotherapy for pulmonary metastases and to the best of our knowledge, only 28 cases have been described, most of which occurred in patients with osteosarcoma or germ cell tumors.
  • We present herein the case of a 56-year-old woman in whom bilateral and recurrent SSP was caused by the rupture of pulmonary lacunae induced by chemotherapy, given for bilateral lung metastases secondary to breast carcinoma.
  • Our experience of this case led us to conclude that: patients with pulmonary metastases may develop bilateral and/or recurrent pneumothoraces following chemotherapy; computed tomography scan is essential for defining the cause of SSP; and closed chest tube drainage remains the therapy of choice, while chemical pleurodesis may also be used to prevent recidivant SSP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Pneumothorax / chemically induced
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Drainage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Methotrexate / administration & dosage. Middle Aged. Mitomycin / administration & dosage. Mitoxantrone / administration & dosage. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1997 Jan-Feb;54(1):15-8 [8978586.001]
  • [Cites] Eur J Cancer. 1997 Jan;33(1):169-70 [9071922.001]
  • [Cites] Clin Radiol. 1996 Apr;51(4):302-4 [8617048.001]
  • [Cites] Clin Radiol. 1990 Aug;42(2):93-6 [2168303.001]
  • [Cites] Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):249-51 [8574239.001]
  • [Cites] AJR Am J Roentgenol. 1980 Sep;135(3):593-604 [6773384.001]
  • [Cites] Chest. 1985 Nov;88(5):709-13 [2996838.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1993;5(3):181-2 [8347542.001]
  • [Cites] Cancer. 1975 Mar;35(3 suppl):936-45 [1078642.001]
  • (PMID = 10819490.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen; MMM protocol 2
  • [Number-of-references] 10
  •  go-up   go-down


58. Yang Q, Sakurai T, Yoshimura G, Suzuma T, Umemura T, Nakamura M, Nakamura Y, Mori I, Kakudo K: Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol Rep; 2003 Jan-Feb;10(1):121-5
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
  • Apoptosis induced by anticancer agents is a mechanism of treatment activity, overexpression of antiapoptotic genes could produce drug resistant tumors.
  • We have demonstrated that the susceptibility of Bcl-2-negative tumors to a series of anticancer drugs was significantly higher than that of Bcl-2-positive tumors.
  • The purpose of this study was to examine if negative Bcl-2 expression has treatment benefit in breast cancer patients received chemotherapy and endocrine treatment.
  • A cohort of 147 Japanese women with invasive ductal carcinoma was studied.
  • All the patients received postoperative adjuvant therapy consisting of combination chemotherapy with cyclophosphamide, epirubicin, and fluorouracil, and tamoxifen therapy.
  • The expression of Bcl-2, estrogen receptor (ER) and MIB-1 was evaluated in breast cancer surgical specimens.
  • Our results imply that Bcl-2 is a significant favorable prognostic factor for breast cancer with chemotherapy and endocrine therapy.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide. Epirubicin. Female. Fluorouracil. Humans. Ki-67 Antigen / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / metabolism. Survival Rate. Tamoxifen

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12469156.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


59. Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Uchiyama K, Yamaue H: Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol; 2006 May 1;93(6):485-90
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
  • In our study, we investigated whether postoperative chemotherapy improved survival in patients with invasive ductal carcinoma of the pancreas.
  • Between 1987 and 2004, 111 patients underwent pancreatic resection against invasive ductal carcinoma of the pancreas in Wakayama Medical University Hospital.
  • Median survival time (MST) was 19.4 months, 8.6 months, and 7.2 months, in JPS Stage III (UICC Stage IIA and IIB), JPS Stage IVa (UICC Stage IIA and IIB), and JPS Stage IVb (UICC Stage IV), respectively (P < 0.01).
  • The MST of the chemotherapy group was 12 months, and the MST of the non-chemotherapy group was 8.4 months (P < 0.05).
  • Moreover, in JPS Stage IV (UICC Stage IIA, IIB, III, and IV) highly advanced pancreatic cancer, the MST of the chemotherapy group was 10.9 months, and the MST of the group without chemotherapy was 6.6 months (P < 0.01).
  • Since pancreatic cancer is characterized by an aggressive tumor with a high recurrent rate, postoperative chemotherapy is effective for an improvement of survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Pancreatectomy / mortality. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16615151.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


60. Schneider-Kolsky ME, Hart S, Fox J, Midolo P, Stuckey J, Hofman M, Ganju V: The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res; 2010;12(3):R37
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET.
  • INTRODUCTION: The aims of this study were to investigate whether drug sequence (docetaxel followed by anthracyclines or the drugs in reverse order) affects changes in the maximal standard uptake volume (SUVmax) on [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) during neoadjuvant chemotherapy in women with locally advanced breast cancer.
  • METHODS: Women were randomly assigned to receive either drug sequence, and FDG-PET scans were taken at baseline, after four cycles and after eight cycles of chemotherapy.
  • Tumour response to chemotherapy was evaluated based on histology from a surgical specimen collected upon completion of chemotherapy.
  • Thirty-one received docetaxel followed by anthracyclines (Arm A) and 29 received drugs in the reverse order (Arm B).
  • Most women (83%) had ductal carcinoma and 10 women (17%) had lobular or lobular/ductal carcinoma.
  • All but one tumour were downstaged during therapy.
  • Overall, there was no significant difference in response between the two drug regimens.
  • CONCLUSIONS: Our results show that SUVmax uptake by breast tumours during chemotherapy can be dependent on the drugs used.
  • Care must be taken when interpreting FDG-PET in settings where patients receive varied drug protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Lobular / diagnosis. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Anthracyclines / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoadjuvant Therapy. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Sci. 2006 Sep;97(9):813-20 [16805818.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] Oncol Rep. 2007 Jan;17(1):253-9 [17143506.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):75-84 [16897427.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1915-24 [17579854.001]
  • [Cites] Cancer Biol Ther. 2007 Sep;6(9):1442-8 [17827982.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1573-7 [18552360.001]
  • [Cites] Clin Ter. 2008 Nov-Dec;159(6):453-6 [19169608.001]
  • [Cites] Eur Radiol. 2009 Jun;19(6):1347-57 [19214522.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1551-7 [19326117.001]
  • [Cites] Ann Surg Oncol. 2010 Jan;17(1):247-53 [19777177.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1676-88 [10764428.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1689-95 [10764429.001]
  • [Cites] J Nucl Med. 2002 Apr;43(4):500-9 [11937594.001]
  • [Cites] Cancer Treat Rev. 2003 Oct;29(5):407-15 [12972359.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S103-11 [15103507.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1352-7 [15319241.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 May;130(5):273-8 [14986112.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):983-1001, vii [15488553.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2101-11 [8229124.001]
  • [Cites] Ultrasound Obstet Gynecol. 1996 Jun;7(6):429-34 [8807760.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):621-6 [9484820.001]
  • [Cites] Cancer J Sci Am. 1998 Mar-Apr;4(2):125-31 [9554929.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2227-34 [9610703.001]
  • [Cites] Am J Surg. 1998 Dec;176(6):502-9 [9926779.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Semin Nucl Med. 2005 Apr;35(2):84-99 [15765372.001]
  • [Cites] Oncologist. 2005 Oct;10 Suppl 2:9-17 [16272454.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5366-72 [17088570.001]
  • (PMID = 20565953.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Taxoids; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 15H5577CQD / docetaxel; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2917032
  •  go-up   go-down


61. Kerr JR: Neonatal effects of breast cancer chemotherapy administered during pregnancy. Pharmacotherapy; 2005 Mar;25(3):438-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal effects of breast cancer chemotherapy administered during pregnancy.
  • Cyclophosphamide and doxorubicin are pregnancy category D agents; however, potential benefits may warrant treatment with these agents during pregnancy under special circumstances.
  • During her first trimester of pregnancy, a 37-year-old Caucasian woman was diagnosed with stage IIB infiltrating ductal carcinoma in situ (breast cancer) that was estrogen and progesterone receptor negative and human epidermal growth factor receptor-2 positive.
  • He had neutropenia and anemia, quite possibly as a result of his mother's chemotherapy 1 week before delivery.
  • The infant grew and developed normally during his first year of life and remained in good health.
  • An objective causality assessment revealed that it was probable that the infant's adverse events (prematurity, neutropenia, and anemia) were related to his mother's doxorubicin and cyclophosphamide therapy; however, these were the only adverse events potentially linked to in utero exposure to chemotherapy during the second and third trimesters.
  • Due to the special considerations of both mother and infant, optimal treatment for patients with pregnancy-associated breast cancer requires the expert opinion of a multidisciplinary care team.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Maternal-Fetal Exchange. Pregnancy Complications, Neoplastic / drug therapy


62. Kim HJ, Im YH, Han BK, Choi N, Lee J, Kim JH, Choi YL, Ahn JS, Nam SJ, Park YS, Choe YH, Ko YH, Yang JH: Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncol; 2007;46(7):996-1003
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
  • BACKGROUND: This study evaluated the accuracy of magnetic resonance imaging (MRI) for estimating residual tumor size after neoadjuvant chemotherapy in patients with locally advanced breast cancer and assessed whether the tumor pattern on MRI after chemotherapy influenced the accuracy of the MRI measurement of the residual tumor size.
  • PATIENTS AND METHODS: Fifty patients who received neoadjuvant chemotherapy with doxorubicin and docetaxel for locally advanced breast cancer were evaluated with MRI before and after chemotherapy.
  • CONCLUSIONS: MRI is an accurate method for predicting the extent of residual tumor after neoadjuvant chemotherapy; however, it may overestimate the residual disease, especially in cases showing a nest or rim tumor pattern and in those having combined lesions with ductal carcinoma in situ or multiple scattered nodules after neoadjuvant chemotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / drug therapy. Magnetic Resonance Imaging. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Prognosis. Reproducibility of Results. Taxoids / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851879.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin
  •  go-up   go-down


63. Tamura N, Hasebe T, Okada N, Houjoh T, Akashi-Tanaka S, Shimizu C, Shibata T, Sasajima Y, Iwasaki M, Kinoshita T: Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy. Cancer Sci; 2009 Oct;100(10):1823-33
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy.
  • The present study investigated fibrotic foci (FFs), the grading system for lymph vessel tumor emboli (LVTEs), and the histological characteristics of nodal metastatic tumors that were significantly associated with the outcomes of 115 patients with invasive ductal carcinoma (IDC) who had received neoadjuvant chemotherapy.
  • The presence of FFs, as assessed by a biopsy performed before neoadjuvant chemotherapy, significantly increased the hazard rates (HRs) for tumor-related death in all the cases and in cases with nodal metastasis.
  • The grading system for LVTEs, which was assessed using surgical specimens obtained after neoadjuvant chemotherapy, was significantly associated with increasing hazard rates (HRs) for tumor recurrence and tumor-related death in all the cases and in cases with nodal metastasis.
  • These results indicated that FFs, the grading system for LVTEs, and the histological characteristics of tumor cells in lymph nodes play important roles in predicting the tumor progression of IDCs of the breast in patients treated with neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymphatic Vessels / pathology. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19604245.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


64. Tanigawa T, Miyamoto Y, Abe M, Hasuo T, Doiguchi M, Sakamoto F: [A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1515-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
  • We experienced a case of inflammatory carcinoma, which has been well controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab.
  • A 54-year-old woman was diagnosed as inflammatory carcinoma with T4d, N3c, M0 in Stage III c.
  • The lesion was diagnosed as invasive ductal carcinoma, scirrhous, ER(-), PgR(-), HER2(3+) by core needle biopsy, The skin lesion was diagnosed as dermal lymphatic carcinomatosis by skin biopsy.
  • The following chemotherapy was performed: FEC(5-FU 500 mg/m2, epirubicin 70 mg/m2, cyclophosphamide 500 mg/m2) followed by docetaxel(DOC 70 mg/m/2), every 3 weeks, each 6 times; after that, sequentially, vinorelbine (25 mg/m2)+trastuzumab (2 mg/kg every week), UFT(300 mg, daily)+cyclophosphamide (100 mg 2 weeks on, 1 week off)+trastuzumab (continued) and S-1 (120 mg/body 4 weeks on, 2 weeks off)+trastuzumab (continued).
  • The patient has been well controlled by the chemotherapy with good QOL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma / drug therapy. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Inflammation. Middle Aged. Oxonic Acid / administration & dosage. Skin Neoplasms / drug therapy. Taxoids / administration & dosage. Tegafur / administration & dosage. Trastuzumab. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755823.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 5VT6420TIG / Oxonic Acid; 8N3DW7272P / Cyclophosphamide; P188ANX8CK / Trastuzumab; Q6C979R91Y / vinorelbine
  •  go-up   go-down


65. Semple SI, Staff RT, Heys SD, Redpath TW, Welch AE, Ahearn TS, Hutcheon A, Gilbert FJ: Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol; 2006 Sep;17(9):1393-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration.
  • BACKGROUND: The aim of the study was to investigate whether pre-therapy vascular delivery assessment [using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)] can predict reduction in breast cancer metabolism [detected using 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography ((18)F(-)FDG-PET)] after a single cycle of chemotherapy.
  • Reduction in (18)F-FDG PET metabolism has previously been shown to correlate with histological response to primary chemotherapy.
  • PATIENTS AND METHODS: Seventeen patients with large or locally advanced invasive ductal carcinomas of the breast were imaged using DCE-MRI and (18)F-FDG-PET prior to therapy and 20 days after the first cycle of chemotherapy.
  • RESULTS: A significant association (P <0.05) was observed between pre-therapy DCE-MRI vascular parameters and the reduction in PET metabolism resulting from administration of one cycle of chemotherapy.
  • CONCLUSIONS: A relationship was demonstrated between pre-therapy DCE-MRI vascular parameters and the reduction in PET metabolism after a single cycle of chemotherapy.
  • This suggests that reduction in PET metabolism as a result of chemotherapy may be dependent, at least in part, on pre-therapy vascular delivery.
  • These pre-therapy vascular characteristics may be suitable for use as a surrogate measure for initial chemotherapy delivery, a key factor in chemotherapeutic efficacy.

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788001.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


66. Li HP, Ma LW, Zhang SL, Jia TZ, Deng HJ, Zhang ZH, Liang L, Wang MP, Xiao Y, Cao BS, Chen S, Wang YF: [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients]. Zhonghua Zhong Liu Za Zhi; 2006 Nov;28(11):848-51
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
  • OBJECTIVE: A retrospective analysis of 160 pre-menopausal breast cancer patients was carried out to elucidate the the menstrual outcome in those cases who had undergone adjuvant chemotherapy after surgery, and evaluate the relationship between chemotherapy-induced amenorrhea (CIA) and recurrence of the disease.
  • METHODS: 160 pre-menopausal breast cancer patients were collected, 62/159 (39.0%) of them were node positive, 91/158 (57.6%) were ER positive, and 95/155 (61.3%) were PR positive.
  • 111 cases had infiltrative ductal carcinoma, 26 cases had infiltrative lobular carcinoma, and 22 cases with others.
  • Types and cycles of chemotherapy regimen as well as menstrual abnormalities were recorded before, during, and after chemotherapy completion.
  • Follow up duration was 12-72 months after chemotherapy completion for all patients.
  • RESULTS: 107 (66.9%) developed CIA, 24 cases returned to normal menses (22.4%), 83 cases continued CIA during more than 12-month follow up (77.6%).
  • During the follow up, disease free survival (DFS) rate was 85.9% in CIA group and 79.2% in non-CIA group, with no statistically significant difference.
  • CONCLUSION: Adjuvant chemotherapy causes ovarian function suppression, and may further leading to amenorrhoea.
  • Women who experienced amenorrhoea after chemotherapy had a significantly better disease-free survival (DFS) rate showed by univariate analysis than women who continued normal menstruation.
  • Chemotherapy is insufficient therapy for very young patients who are in high risk with hormone responsive disease, particularly when chemotherapy fails to induce amenorrhea.
  • Further research is needed to evaluate interventional chemotherapy to improve the quality of life in women with early stage breast cancer who experienced ovarian toxicity.
  • The post-chemotherapy menstruation status is a clinically valuable, objective and salient marker for sufficient endocrine effect of chemotherapy in ER/PR-positive premenopausal patients.
  • [MeSH-major] Amenorrhea / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy
  • [MeSH-minor] Adult. Age Factors. Chemotherapy, Adjuvant. Disease-Free Survival. Estradiol / blood. Female. Follicle Stimulating Hormone / blood. Follow-Up Studies. Humans. Middle Aged. Premenopause. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416008.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


67. Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP: Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer; 2010 Mar 1;116(5):1243-51
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
  • BACKGROUND: The timing and accuracy of axillary sentinel lymph node biopsy (SLNB) in patients who are receiving neoadjuvant chemotherapy (NACT) for breast cancer are controversial.
  • To examine the accuracy of SLNB after NACT, the authors performed SLNB after chemotherapy on all of patients who received NACT at their institution starting in January 1997.
  • METHODS: Seventy-nine women who underwent NACT between 1997 and 2008 comprised this study and were divided as follows: 4 women had stage I disease, 60 women had stage II disease, and 15 women had stage III disease, including 10 women who had multicentric disease.
  • Thirty-nine women (49.4%) had clinical evidence of axillary metastasis (N1-N2) at the time of diagnosis.
  • The regimen, the duration of treatment, and the number of cycles of NACT depended on clinical response.
  • The choice of breast conservation therapy or mastectomy was based on the patient's response to treatment and patient preference.
  • RESULTS: Seventy-three patients underwent breast conservation therapy, and 6 patients underwent mastectomy.
  • Fourteen patients (17.7%) had no residual carcinoma (invasive or ductal carcinoma in situ) in their breast, 5 patients (6.3%) had residual ductal carcinoma in situ (only), and 60 patients (75.9%) had residual invasive carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / pathology. Neoadjuvant Therapy. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Humans. Lymph Node Excision. Lymphatic Metastasis / diagnosis. Middle Aged. Neoplasm Staging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087958.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Huang F, Kushner YB, Langleben A, Foulkes WD: Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer. Nat Rev Clin Oncol; 2009 Aug;6(8):488-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer.
  • BACKGROUND: Infiltrating ductal carcinoma of the breast, staged as pT1N3, was diagnosed in a 41-year-old premenopausal French-Canadian woman.
  • Following enrollment in an in-house study protocol, she received high-dose anthracycline-based induction chemotherapy followed by tandem autologous bone marrow transplantation with high-dose alkylator and platinum-based conditioning regimens.
  • Upon full remission, protocol-mandated locoregional breast and prophylactic cranial radiation was delivered.
  • DIAGNOSIS: A BRCA2 8765delAG mutation was identified, in the context of unusual and sustained complete remission from widely metastatic breast cancer.
  • MANAGEMENT: The patient is now followed at a multidisciplinary high-risk prevention clinic because BRCA2 mutations are associated with increased risk of ovarian and breast cancers.
  • This case supports the possibility of differential treatment response in BRCA2-positive breast cancer, although this remains to be conclusively demonstrated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / secondary. Genes, BRCA2
  • [MeSH-minor] Adult. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Mastectomy, Segmental. Pedigree. Transplantation, Autologous


69. Kim HS, Yom CK, Kim HJ, Lee JW, Sohn JH, Kim JH, Park YL, Ahn SH: Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy. Breast Cancer Res Treat; 2010 Jun;121(3):777-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
  • The aim of this study was to evaluate the difference in outcomes based on p53 overexpression of patients with breast cancer who received adjuvant therapy following local treatment for invasive ductal carcinoma, not otherwise specified.
  • We analyzed the correlation between p53 overexpression and relapse, response to adjuvant therapy, breast cancer-specific survival (BCSS), and relapse-free survival (RFS) in patients with primary breast cancer.
  • Based upon subgroup analyses, combined age (<35, 35-50, and >50 years) and adjuvant therapy (hormone therapy only, chemotherapy only, and hormone therapy following chemotherapy), the greatest reduction of survival based on p53 overexpression was noted in patients 35-50 years of age who received hormone therapy following chemotherapy (P < 0.05).
  • Multivariate analysis showed that p53 overexpression is an independent prognostic factor in patients treated with hormone therapy and chemotherapy (relative risk for BCSS, 2.003; 95% CI, 1.105-3.631; P = 0.022).
  • The p53-overexpressing patients with breast cancer between 35 and 50 years of age who received tamoxifen following chemotherapy had the greatest adverse effect on outcome.
  • Overexpression of p53 is significantly associated with tamoxifen resistance in premenopausal women with breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / metabolism. Tamoxifen / therapeutic use. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Age Distribution. Aged. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806450.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Tumor Suppressor Protein p53; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


70. Matsumoto S, Kiyosue H, Komatsu E, Wakisaka M, Tomonari K, Hori Y, Matsumoto A, Mori H: Radiotherapy combined with transarterial infusion chemotherapy and concurrent infusion of a vasoconstrictor agent for nonresectable advanced hepatic hilar duct carcinoma. Cancer; 2004 Jun 1;100(11):2422-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy combined with transarterial infusion chemotherapy and concurrent infusion of a vasoconstrictor agent for nonresectable advanced hepatic hilar duct carcinoma.
  • BACKGROUND: The treatment of patients with advanced hepatic hilar duct carcinoma is a challenging problem.
  • The current study was performed to evaluate the outcome of patients with advanced hepatic hilar duct carcinoma who received external beam radiotherapy (EBRT) combined with transarterial chemotherapy and infusion of a vasoconstrictor.
  • METHODS: Between April 1993 and December 2002, 23 patients with histopathologically confirmed hilar duct carcinoma entered the study.
  • The median total dose of EBRT was 41.4 grays (Gy).
  • Transarterial chemotherapy was performed twice during EBRT.
  • It was comprised of an infusion of a cocktail of 20 mg of epirubicin, 10 mg of mitomycin C, and 500 mg of 5-fluorouracil and was administered 1 minute after injection of epinephrine via a catheter introduced in the hepatic arteries.
  • After the combined treatment, the patients underwent biliary endoprosthesis after evaluation of the initial response to treatment by percutaneous transhepatic cholangiography (PTC).
  • The outcome parameters were survival rates and time, as well as frequency and type of complications.
  • RESULTS: Excluding 1 patient who discontinued the treatment, the initial responses of 22 patients were 1 CR (5%), 8 PR (36%), 11 NC (50%), and 2 PD (9%).
  • The overall survival rates at 1 year, 2 years, and 3 years after treatment were 59%, 36%, and 18%, respectively.
  • CONCLUSIONS: The combination of radiotherapy, transarterial infusion chemotherapy, and concurrent infusion of a vasoconstrictor can be delivered safely with good efficacy for patients with advanced hilar duct carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / radiotherapy. Bile Ducts, Intrahepatic / pathology. Hepatic Artery / pathology. Radiotherapy, Conformal
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Epinephrine / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infusion Pumps, Implantable. Liver / pathology. Male. Middle Aged. Mitomycin / administration & dosage. Prognosis. Survival Rate. Treatment Outcome. Vasoconstrictor Agents / administration & dosage

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15160347.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil; YKH834O4BH / Epinephrine
  •  go-up   go-down


71. Palma M, Mancuso A, Grifalchi F, Lugini A, Pizzardi N, Cortesi E: Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report. Tumori; 2002 Nov-Dec;88(6):527-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report.
  • A 46-year-old woman had an episode of atrial fibrillation during infusion of docetaxel as adjuvant chemotherapy for an infiltrating ductal carcinoma of the breast.
  • All cardiological tests performed before treatment were normal and there was no evidence of thyroid dysfunction nor any objective or anamnestic data indicating acute or chronic cardiovascular disease.
  • None of the drugs administered has ever shown any proarrhythmic activity.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / surgery. Chemotherapy, Adjuvant / adverse effects. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Atrial Fibrillation.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12597151.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


72. Falconi M, Sartori N, Cantore M, Salvia R, Talamini G, Bassi C, Smerieri F, Pederzoli P: [Does locoregional chemotherapy improve survival in patients with non-resectable pancreatic carcinoma? Results of an open controlled study]. Chir Ital; 2001 Jan-Feb;53(1):23-32
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Does locoregional chemotherapy improve survival in patients with non-resectable pancreatic carcinoma? Results of an open controlled study].
  • [Transliterated title] La chemioterapia locoregionale migliora la sopravvivenza dei pazienti affetti da carcinoma pancreatico non resecabile? Risultati di uno studio aperto, controllato.
  • About 90% of patients suffering from pancreatic carcinoma are diagnosed with disease that is not amenable to surgical intervention due to local infiltration or the presence of hepatic metastases.
  • Palliative intra-arterial chemotherapy was developed to improve the response in these patients by increasing the antiblastic dose and minimizing the side effects.
  • The aim of this study is to evaluate the efficacy of this treatment comparison to a control group.
  • From December 1994 to February 1997, 135 patients with ductal carcinoma, in whom 68 were stage III and 67 stage IV, with a median age of 63.3 years (range 38.4-79), were enrolled in an open study.
  • Four patients had a partial response (6.3%), 27 enjoyed a stabilization of their disease (42.2%) and 13 showed disease progression (20.3%).
  • The treatment reported here, therefore, does not seem to change the prognosis of patients affected by no resectable pancreatic carcinoma, but it may demonstrate good tolerability and minimal toxicity.
  • [MeSH-major] Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11280825.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


73. Cerussi AE, Tanamai VW, Mehta RS, Hsiang D, Butler J, Tromberg BJ: Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient. Acad Radiol; 2010 Aug;17(8):1031-9
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient.
  • RATIONALE AND OBJECTIVES: Imaging tumor response to neoadjuvant chemotherapy in vivo offers unique opportunities for patient care and clinical decision-making.
  • Detailed imaging studies may allow oncologists to optimize therapeutic drug type and dose based on individual patient response.
  • MATERIALS AND METHODS: Diffuse Optical Spectroscopic Imaging (DOSI) is a noninvasive, bedside functional imaging technique that quantifies the concentration and molecular state of tissue hemoglobin, water, and lipid.
  • Pilot clinical studies have shown that DOSI may be a useful tool for quantifying neoadjuvant chemotherapy response, typically by comparing the degree of change in tumor water and deoxy-hemoglobin concentration before and after therapy.
  • Patient responses at 1 week and mid-therapy have been used to predict clinical outcome.
  • In this report, we assess the potential value of frequent DOSI monitoring by performing measurements on 19 different days in a 51-year-old subject with infiltrating ductal carcinoma (initial tumor size 60 x 27 mm) who received neoadjuvant chemotherapy (anthracyclines and bevacizumab) over an 18-week period.
  • RESULTS: A composite index, the Tissue Optical Index (TOI), showed a significant ( approximately 50%) decrease over the nearly 18 weeks of chemotherapy.
  • Tumor response was sensitive to the type of chemotherapy agent, and functional indices fluctuated in a manner consistent with dynamic tumor physiology.
  • Final pathology revealed 4 mm of residual disease, which was detectible by DOSI at the conclusion of chemotherapy before surgery.
  • CONCLUSION: This case study suggests that DOSI may be a bedside-capable tool for frequent longitudinal monitoring of therapeutic functional response to neoadjuvant chemotherapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 AUR. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1689-95 [10764429.001]
  • [Cites] Neoplasia. 2000 Jan-Apr;2(1-2):26-40 [10933066.001]
  • [Cites] Radiology. 2001 Jan;218(1):261-6 [11152812.001]
  • [Cites] J Biomed Opt. 2002 Jan;7(1):60-71 [11818013.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1806-14 [14602864.001]
  • [Cites] Radiology. 2004 Nov;233(2):424-31 [15516615.001]
  • [Cites] AJR Am J Roentgenol. 2005 Mar;184(3):868-77 [15728611.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jun;184(6):1774-81 [15908529.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051503 [16292947.001]
  • [Cites] J Biomed Opt. 2006 May-Jun;11(3):33001 [16822050.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):044005 [16965162.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):869-74 [17012049.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] Acad Radiol. 2007 Apr;14(4):398-405 [17368207.001]
  • [Cites] J Biomed Opt. 2007 Mar-Apr;12(2):020509 [17477706.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):696-7 [18258975.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):806-13 [18258990.001]
  • [Cites] J Biomed Opt. 2008 May-Jun;13(3):030504 [18601521.001]
  • [Cites] Med Phys. 2008 Jun;35(6):2443-51 [18649477.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1573-7 [18552360.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6580-9 [18927299.001]
  • [Cites] Phys Med Biol. 2008 Dec 7;53(23):6713-27 [18997265.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):050509 [19021379.001]
  • [Cites] Eur J Cancer. 2008 Dec;44(18):2742-52 [18977653.001]
  • [Cites] Ann Surg Oncol. 2009 Jun;16(6):1619-28 [19333654.001]
  • [Cites] Radiology. 2009 Jun;251(3):653-62 [19276320.001]
  • [Cites] Appl Opt. 2009 Jul 20;48(21):4270-7 [19623242.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1551-7 [19326117.001]
  • [Cites] J Biomed Opt. 2004 Jan-Feb;9(1):230-8 [14715078.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(1):67-76 [14997056.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1349-60 [15054453.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):464-73 [15189083.001]
  • [Cites] Med Phys. 1994 Feb;21(2):185-91 [8177151.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6468-73 [9177241.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • (PMID = 20542448.001).
  • [ISSN] 1878-4046
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR001192-27; United States / NCI NIH HHS / CA / R01 CA142989; United States / NCI NIH HHS / CA / U54 CA136400-01; None / None / / P41 RR001192-31; United States / NCI NIH HHS / CA / R01 CA142989-01; United States / NCI NIH HHS / CA / U54 CA105480-04; United States / NCRR NIH HHS / RR / P41 RR001192-31; None / None / / P41 RR001192-27; United States / NCRR NIH HHS / RR / P41 RR001192-30; United States / NCI NIH HHS / CA / U54 CA105480-05; United States / NCI NIH HHS / CA / U54-CA105480; United States / NCI NIH HHS / CA / U54 CA105480-02; None / None / / P41 RR001192-26; United States / NCRR NIH HHS / RR / P41 RR001192-29; United States / NCRR NIH HHS / RR / P41 RR001192-26; United States / NCI NIH HHS / CA / U54 CA105480; United States / NCRR NIH HHS / RR / P41 RR001192-305021; United States / NCI NIH HHS / CA / U54 CA105480-03; United States / NCI NIH HHS / CA / U54CA136400; United States / NCI NIH HHS / CA / U54 CA136400; United States / NCI NIH HHS / CA / R01 CA142989-02; United States / NCRR NIH HHS / RR / RR001192-305021; United States / NCI NIH HHS / CA / U54 CA105480-01; United States / NCRR NIH HHS / RR / P41 RR001192; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCI NIH HHS / CA / 2P30CA62203; None / None / / P41 RR001192-28; United States / NCRR NIH HHS / RR / P41-RR01192; United States / NCRR NIH HHS / RR / P41 RR001192-28
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ NIHMS214449; NLM/ PMC2924201
  •  go-up   go-down


74. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S, Spielmann M: The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer; 2004 Feb;40(3):342-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.
  • The aim of this study was to determine the chemosensitivity of infiltrating lobular breast carcinoma (ILC) in comparison with infiltrating ductal carcinoma (IDC).
  • Between 1987 and 1995, 457 patients with invasive T2>3 cm-T4 breast carcinomas were treated with primary chemotherapy (CT), surgery, radiation therapy.
  • Clinical response, the possibility of breast preservation, pathological response and survival were evaluated according to the histological type.
  • ILC was an independent predictor of a poor clinical response (P=0.02) and ineligibility for breast-conserving surgery after neoadjuvant chemotherapy (P=0.03).
  • Preoperative CT did not allow a high rate of conservative treatment for ILC and therefore the use of neoadjuvant CT for ILC patients should be questioned.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Immunohistochemistry. Mastectomy / methods. Middle Aged. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14746851.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


75. Pendas S, Jakub J, Giuliano R, Gardner M, Swor GB, Reintgen DS: The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy. Cancer Control; 2004 Jul-Aug;11(4):231-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy.
  • BACKGROUND: A significant number of patients who are initially diagnosed with pure DCIS will harbor missed or occult invasive disease at their definitive surgery.
  • The role of SLN biopsy after neoadjuvant chemotherapy in patients with advanced breast cancer is controversial.
  • METHODS: A review of the literature was performed to determine the role of SLN biopsy in patients with DCIS or advanced breast cancer receiving neoadjuvant chemotherapy.
  • The success rate of SLN biopsy after neoadjuvant chemotherapy was investigated as well as the percentage of positive SLNs in patients with DCIS.
  • RESULTS: Two consecutive studies revealed metastatic disease to the regional lymph nodes in up to 13% of DCIS patients.
  • In addition, 10% of DCIS patients were upstaged to infiltrating ductal carcinoma at their definitive therapy.
  • The ability of the SLN to predict the status of the remaining non-SLNs after neoadjuvant chemotherapy is unknown.
  • CONCLUSIONS: SLN biopsy is a minimally invasive technique that can be used to evaluate the regional nodal status of DCIS patients.
  • Performing a SLN biopsy during the initial surgical procedure may avoid a second operation in some DCIS patients who are diagnosed with invasive disease at their definitive operation.
  • The success rate of sentinel node identification does not seem to be altered after neoadjuvant therapy.
  • Therefore, until further prospective randomized trials are conducted, it cannot be assumed that all the regional nodes have the same biologic response to chemotherapy as the SLN.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / secondary. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Neoadjuvant Therapy. Outcome and Process Assessment (Health Care). Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15284714.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


76. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretière JM, Bouita L, Cohen-Solal C, Cherel P, Rouëssé J: Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol; 2006 Aug;17(8):1228-33
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution.
  • BACKGROUND: We compared the impact of neoadjuvant chemotherapy on pathologic response and outcome in operable invasive lobular breast carcinoma (ILC) and invasive ductal breast carcinoma (IDC).
  • PATIENTS AND METHODS: We extracted from our database all patients with pure invasive lobular (n=118, 14%) or pure invasive ductal carcinomas (n=742, 86%).
  • Their treatment included neoadjuvant chemotherapy, adapted surgery, radiotherapy and adjuvant hormonal treatment.
  • The outcome at 60 months was significantly better for ILC, but histologic type was not an independent factor for survival in multivariate analysis.
  • CONCLUSIONS: ILC appeared less responsive to chemotherapy but presented a better outcome than IDC.
  • While new information on biological features of ILC is needed, we consider that neoadjuvant endocrine therapy in hormone receptor-positive ILC may be a more adapted approach than neoadjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740599.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Colleoni M, Bagnardi V, Rotmensz N, Viale G, Mastropasqua M, Veronesi P, Cardillo A, Torrisi R, Luini A, Goldhirsch A: A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. Eur J Cancer; 2010 Aug;46(12):2216-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer.
  • BACKGROUND: Tools able to predict pathological complete response (pCR) to preoperative chemotherapy might improve treatment outcome.
  • PATIENTS AND METHODS: Data from 783 patients with invasive ductal carcinoma treated with preoperative chemotherapy and operated at the European Institute of Oncology were used to develop a nomogram using logistic regression model based on both categorical (clinical T and N, HER2/neu, grade and primary therapy) and continuous variables (age, oestrogen receptor (ER), progesterone receptor (PgR), Ki-67 expression and number of chemotherapy courses).
  • RESULTS: At multivariable analysis the probability of pCR was directly associated with Ki-67 expression (OR for 10% increase in the percentage of positive cells, 1.15, 95% confidence interval (CI), 1.03, 1.29) and number of chemotherapy courses (OR for one cycle increase, 1.31, 95% CI, 1.12, 1.53) and inversely associated with ER and PgR expression (ORs for 10% increase in the percentage of positive cells, 0.86, 95% CI 0.79, 0.93 and 0.82, 95% CI 0.69, 0.99, respectively).
  • CONCLUSION: The use of a nomogram based on the number of preoperative courses, degree of Ki-67 and steroid hormone receptors expression may be useful for predicting the probability of pCR and for the design of the proper therapeutic algorithm in locally advanced breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Ki-67 Antigen / metabolism. Nomograms. Receptors, Steroid / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Middle Aged. Preoperative Care / methods. Remission Induction. Sensitivity and Specificity. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20471822.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Steroid
  •  go-up   go-down


78. Tozaki M, Uno S, Kobayashi T, Aiba K, Yoshida K, Takeyama H, Shioya H, Tabei I, Toriumi Y, Suzuki M, Kawakami M, Fukuda K: Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI. Radiat Med; 2004 Jul-Aug;22(4):246-53
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI.
  • PURPOSE: To evaluate the efficacy of dynamic multidetector-row CT (MDCT) in assessing residual cancer extent after neoadjuvant chemotherapy (NAC), and to compare MDCT results with those derived from dynamic three-dimensional MRI using the volumetric interpolated breath-hold examination (VIBE) sequence.
  • MATERIALS AND METHODS: MDCT before and after NAC was performed in 19 consecutive patients with breast cancer.
  • In replaced lesions, accuracy for the detection of tumor extent with a deviation of less than 2 cm in length was 0% (0/7) with early-phase CT/MRI and 100% (7/7) with late-phase CT/MRI.
  • One case of ductal carcinoma in situ (DCIS) could be detected only with late phase MRI.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Magnetic Resonance Imaging / methods. Neoadjuvant Therapy. Tomography, Spiral Computed
  • [MeSH-minor] Adult. Aged. Anthracyclines / administration & dosage. Bridged Compounds / administration & dosage. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Contrast Media. Female. Humans. Image Enhancement / methods. Imaging, Three-Dimensional. Middle Aged. Neoplasm, Residual. Radiographic Image Enhancement / methods. Remission Induction. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15468945.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Bridged Compounds; 0 / Contrast Media; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


79. Wang XH, Peng WJ, Xin C, Tan HN, Gu YJ, Tang F, Mao J: [Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Jul;32(7):539-43
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].
  • OBJECTIVE: To assess the value of dynamic contrast-enhanced MRI (DMRI) in predicting early response to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer (LABC) and to assess the accuracy of MRI in evaluation of residual disease after NAC.
  • METHODS: Forty-three women with LABC (44 lesions, all were invasive ductal carcinoma) underwent DMRI before, after the first and final cycles of NAC.
  • For each patient, the tumor volume, early enhancement ratio (E1), maximum enhancement ratio (Emax), and maximum enhancement time (Tmax), dynamic signal intensity-time curve were obtained during treatment.
  • After NAC, the dynamic signal intensity-time types were changed in responders, and tended to be significantly flattening, while no significant change was found in non-responders.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Magnetic Resonance Imaging / methods. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Contrast Media. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029700.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


80. Cocquyt VF, Schelfhout VR, Blondeel PN, Depypere HT, Daems KK, Serreyn RF, Praet MM, Van Belle SJ: The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer. Med Oncol; 2003;20(3):221-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer.
  • The aim of this prospective study was to evaluate biological markers, their correlation with response and outcome, and the change in these markers under the influence of preoperative chemotherapy (PCT) in patients with a large primary breast cancer.
  • One hundred and thirty-five women were treated with PCT, followed by locoregional therapy and adjuvant treatment.
  • Forty-four percent of the patients could be offered breast-conserving surgery (BCS).
  • At a median follow-up of 50 mo the overall survival is 82% and the disease-free survival is 70%.
  • No local recurrence (LR) has developed following BCS.
  • Invasive ductal carcinoma (IDC) was more frequently ER-negative and HER-2-positive than invasive lobular carcinoma (ILC).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Cathepsin D / metabolism. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Mastectomy, Segmental. Middle Aged. Preoperative Care. Prospective Studies. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Remission Induction. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 May;17(5):1474-81 [10334533.001]
  • [Cites] Br J Cancer. 1996 Nov;74(9):1458-65 [8912545.001]
  • [Cites] Breast Cancer Res Treat. 1997 Jul;44(3):185-92 [9266097.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1260-6 [7908410.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):1974-82 [10561247.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1049-56 [1351538.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):93-100 [9440728.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2651-8 [9704715.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2334-56 [11304787.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):1057-9 [11038046.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):429-35 [8397164.001]
  • [Cites] Eur J Cancer. 2001 Jan;37 Suppl 1:S11-7 [11167086.001]
  • [Cites] Int J Cancer. 1995 May 4;61(3):301-5 [7729938.001]
  • [Cites] Acta Oncol. 1992;31(2):125-30 [1622626.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4224-37 [11709566.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1011-21 [10572598.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2505-12 [11289122.001]
  • [Cites] Br J Cancer. 1997;76(7):917-22 [9328152.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3817-27 [11559719.001]
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):580-6 [10567902.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1601-8 [9811309.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):647-63 [10942052.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):17-23 [11773149.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3058-63 [10506600.001]
  • [Cites] Nat Med. 1996 Jul;2(7):811-4 [8673929.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):593-600 [9815725.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):27-33 [9495354.001]
  • [Cites] Mol Endocrinol. 1990 Sep;4(9):1327-35 [2172799.001]
  • (PMID = 14514971.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


81. Loo WT, Jin LJ, Cheung MN, Chow LW, Wang M: Combination of radiological and biochemical methods to assess bone mineral density of mandible in fully edentulous patients after chemotherapy: a 5-year prospective study. Expert Opin Investig Drugs; 2010 Apr;19 Suppl 1:S109-15
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of radiological and biochemical methods to assess bone mineral density of mandible in fully edentulous patients after chemotherapy: a 5-year prospective study.
  • BACKGROUND: Osteoporosis is of concern in breast cancer patients who are undergoing chemotherapy.
  • This study compared the bone mineral density (BMD) index of the mandible and hip hinge between patients who were undergoing chemotherapy or breast cancer, and fully edentulous Chinese patients without cancer over a period of 5 years.
  • METHOD: 120 fully edentulous patients with an average age of 69 who had undergone mastectomy for grade two or three non-metastatic invasive breast ductal carcinoma.
  • The first assessment point was 6 months after chemotherapy treatment.
  • The serum and urine level of bone-specific alkaline phosphatase (BAP), carboxyterminal cross-linked telopeptide of type I collagen (ICTP), as well as liver and renal function tests were determined.
  • CONCLUSION: Breast cancer patients undergoing chemotherapy displayed significant resorption of mandibular bones compared with the healthy control, which might result in difficulties in fitting dentures, as it would cause pain and mucosal friction.
  • Thus, concurrent therapy to decrease mandibular bone loss and special considerations in dentures are warranted for these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Density / drug effects. Mouth, Edentulous / complications. Osteoporosis / chemically induced
  • [MeSH-minor] Absorptiometry, Photon. Aged. Bone Resorption / chemically induced. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Case-Control Studies. China. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Denture, Complete. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Hip / pathology. Humans. Mandible / pathology. Middle Aged. Prospective Studies. Prosthesis Fitting / methods. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374022.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


82. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK: Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer; 2001 Apr 20;84(8):1016-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer.
  • Results of the proton magnetic resonance spectroscopy carried out on normal, benign breast disease and locally advanced breast cancer patients are presented.
  • The in-vivo MR spectra of malignant breast tissue of patients (n = 67) suffering from infiltrating ductal carcinoma are dominated by the water resonance, while the spectra of the unaffected contralateral breast tissue of these patients are mainly dominated by resonance arising from lipids which is similar to the spectra of normal breast tissue obtained from volunteers (controls, n = 16).
  • In addition to the water and lipid peaks, in majority of the patients (approximately 80%) the water suppressed spectra showed a resonance at 3.2 ppm due to choline containing compounds (TCho) before treatment.
  • In patients receiving neoadjuvant chemotherapy, absence/reduction in choline was observed in 89% of the patients.
  • Observation of TCho before treatment and its disappearance (or reduction) after treatment may be a useful indicator of response of locally advanced breast cancer to neoadjuvant chemotherapy.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Choline / metabolism. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Radiotherapy. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] Cancer Res. 1988 Sep 15;48(18):5112-8 [3409237.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):159-64 [10441019.001]
  • [Cites] Lancet. 1989 Jun 10;1(8650):1326-7 [2566851.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3):527-32 [2297695.001]
  • [Cites] Magn Reson Q. 1989 Apr;5(2):152-68 [2701279.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):821-6 [1931601.001]
  • [Cites] Radiology. 1993 May;187(2):493-501 [8475297.001]
  • [Cites] Radiologe. 1993 May;33(5):292-9 [8390704.001]
  • [Cites] Anticancer Res. 1993 Nov-Dec;13(6A):1973-80 [8297103.001]
  • [Cites] Br J Cancer. 1994 Jun;69(6):1151-6 [8198985.001]
  • [Cites] Natl Med J India. 1995 Jan-Feb;8(1):6-9 [7696954.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5140-5 [7585561.001]
  • [Cites] Radiographics. 1996 Nov;16(6):1385-401 [8946543.001]
  • [Cites] Eur J Radiol. 1997 Feb;24(2):94-108 [9097051.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 1):489-96 [9240665.001]
  • [Cites] Radiology. 1997 Sep;204(3):661-6 [9280241.001]
  • [Cites] Eur Radiol. 1997;7 Suppl 5:281-8 [9370560.001]
  • [Cites] Eur Radiol. 1998;8(5):707-25 [9601956.001]
  • [Cites] Radiographics. 1998 Jul-Aug;18(4):903-12 [9672975.001]
  • [Cites] Radiology. 1998 Oct;209(1):269-75 [9769842.001]
  • [Cites] MAGMA. 1998 Aug;6(1):44-52 [9794289.001]
  • [Cites] Radiology. 1998 Nov;209(2):499-509 [9807580.001]
  • [Cites] J Magn Reson Imaging. 1998 Nov-Dec;8(6):1191-7 [9848727.001]
  • [Cites] NMR Biomed. 1998 Nov;11(7):314-40 [9859939.001]
  • [Cites] NMR Biomed. 1998 Nov;11(8):414-22 [10221584.001]
  • [Cites] Radiology. 1988 Dec;169(3):615-20 [2847230.001]
  • (PMID = 11308247.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] N91BDP6H0X / Choline
  • [Other-IDs] NLM/ PMC2363867
  •  go-up   go-down


83. Kashiwagi S, Kawajiri H, Noda S, Takashima T, Onoda N, Nakata B, Kato Y, Ishikawa T, Hirakawa K: [A case of multicentric breast cancer in which an effect of neoadjuvant chemotherapy had a disparity]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2775-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of multicentric breast cancer in which an effect of neoadjuvant chemotherapy had a disparity].
  • A 61-year-old woman was visited our hospital for a left breast tumor.
  • Ultrasonography (US) demonstrated two tumors comprising a tumor 3.3 cm in diameter in the A area and another one 0.9 cm in diameter in the C area of the left breast, and US-guided core needle biopsy (CNB) was performed.
  • The histological findings showed invasive ductal carcinoma, ER (+)/PR (-)/HER2 (+) in the A lesion and ER (+)/PR (+)/HER2 (-) in the C lesion.
  • At this point in time, US demonstrated a new tumor 1.9 cm in diameter in the outside C area of the left breast, and CNB was performed.
  • The histological findings showed invasive ductal carcinoma, ER (+)/PR (+)/HER2 (-) in the outside C lesion.
  • Chemotherapy was estimated as PD, and an operation was performed (Bt + Ax).
  • Histopathological examination showed pCR in the A lesion, invasive lobular carcinoma in the C lesion and solid-tubular carcinoma in the outside C new lesion.
  • Depend on each subtype, HER2/new targeting trastuzumab therapy, radiation therapy and ER/PR targeting hormone therapy were tried as a post operative treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Neoadjuvant Therapy. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Cyclophosphamide / therapeutic use. Epirubicin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224709.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


84. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Hortobagyi GN: Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol; 2005 Jan 1;23(1):41-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
  • PURPOSE: To investigate the impact of histologic type invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) on response to primary chemotherapy (PC) and long-term outcome.
  • PATIENTS AND METHODS: The study included 1,034 patients with stage II and III breast cancer who participated in six clinical trials of PC at our institution between 1985 and 2002.
  • Pathologic complete response (pCR) was defined as no evidence of invasive disease in the breast and axillary lymph nodes.
  • Patients with ILC tended to be older (median age, 53 years v 47 years for patients with IDC) and have more hormone-receptor-positive tumors (92% v 62%; P < .001), lower nuclear grade (nuclear grade 3, 16% v 56%; P < .001), and higher stage at diagnosis (10% v 0% with stage IIIB or IIIC disease; P < .001).
  • At a median follow-up time of 70 months, ILC patients tended to have longer recurrence-free survival (P = .004) and overall survival (P = .001).
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / mortality. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Axilla. Bridged Compounds / therapeutic use. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / mortality. Carcinoma, Ductal / pathology. Disease-Free Survival. Humans. Lymph Nodes / pathology. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / mortality. Taxoids / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 20;23(27):6796; author reply 6796-7 [16170189.001]
  • [ErratumIn] J Clin Oncol. 2013 Aug 10;31(23):2977. Buccholz, Thomas A [corrected to Buchholz, Thomas A]
  • (PMID = 15625359.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


85. Yoshibayashi H, Ishiguro H, Takada M, Takeuchi M, Yamashiro H, Ueno T, Kato H, Yoshikawa K, Kanao S, Yamauchi C, Mikami Y, Toi M: [A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide]. Gan To Kagaku Ryoho; 2008 Jun;35(6):987-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide].
  • A 67-year-old woman visited our hospital with suspicion of right breast cancer.
  • She underwent core needle biopsy, and her disease was diagnosed as breast cancer (invasive ductal carcinoma, ER- and PgR- positive, HER2-negative).
  • We chose neoadjuvant chemotherapy, because the tumor size was over 3 cm in diameter and she wished to conserve her breast.
  • She was elderly, and so without anthracycline base, we used a combination of docetaxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2)) q3w 6 cycles followed by breast-conserving therapy.
  • During treatment, the patient remained very well and showed no major side effects except grade 4 neutropenia on an outpatient basis.
  • After 6 cycles, ultrasonography and mammography indicated the residual tumor, but breast MRI did not detect any tumor.
  • Pathological examination showed absence of invasive tumor or only focal residual tumor cells (QpCR).
  • We concluded that the combination of docetaxel and cyclophosphamide was a good option for neoadjuvant chemotherapy for early breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Neoadjuvant Therapy. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633230.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


86. Shah N, Gibbs J, Wolverton D, Cerussi A, Hylton N, Tromberg BJ: Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. J Biomed Opt; 2005 Sep-Oct;10(5):051503
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study.
  • Monitoring tumor response to therapy can enable assessment of treatment efficacy, maximizing patient outcome and survival.
  • We employ a noninvasive, handheld laser breast scanner (LBS) based on broadband diffuse optical spectroscopy (DOS) in conjunction with contrast-enhanced magnetic resonance imaging (cMRI) to assess tumor response to presurgical neoadjuvant chemotherapy.
  • DOS and cMRI scans are performed after the first and fourth cycles of a doxorubicin/cyclophosphamide regimen in a patient with invasive ductal carcinoma.
  • DOS measurements are used to quantify bulk tissue optical and physiological parameters, which are mapped to T2- and T1-weighted cMRI images.
  • After the fourth cycle of chemotherapy, we observe decreases in peak MRI contrast-enhancement values (37.6%) and apparent lesion volume (21.9 versus 13.7 cm3), which corresponds to physiological changes measured by DOS, including a 20 to 25% reduction in the spatial extent of the tumor and a 38.7% drop in mean total hemoglobin content (THC, 41.6 versus 23.4 microM).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / diagnosis. Breast Neoplasms / drug therapy. Carcinoma, Ductal / diagnosis. Carcinoma, Ductal / drug therapy. Magnetic Resonance Imaging / methods. Spectrum Analysis / methods
  • [MeSH-minor] Chemotherapy, Adjuvant. Contrast Media. Female. Gadolinium DTPA. Humans. Image Enhancement / methods. Lasers. Middle Aged. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Subtraction Technique. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292947.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P41RR01192; United States / NCI NIH HHS / CA / U54CA105480
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


87. Schulz-Wendtland R, Heywang-Köbrunner SH, Aichinger U, Krämer S, Wenkel E, Bautz W: [Do tissue marker clips after sonographically or stereotactically guided breast biopsy improve follow-up of small breast lesions and localisation of breast cancer after chemotherapy?]. Rofo; 2002 May;174(5):620-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Do tissue marker clips after sonographically or stereotactically guided breast biopsy improve follow-up of small breast lesions and localisation of breast cancer after chemotherapy?].
  • [Transliterated title] Verbessert die Clipmarkierung im Rahmen der sonographischen oder stereotaktischen Brustbiopsie die Verlaufsbeurteilung kleiner Mammaläsionen und Lokalisation von Tumoren nach Chemotherapie?
  • PURPOSE: We wanted to determine if tissue marker clips after sonographically or stereotactically guided breast biopsy improve the follow-up of small breast lesions classified BI-RADS 4/5 and the localisation of breast cancer (TNM stage 2 or 3) after neoadjuvant chemotherapy.
  • MATERIAL AND METHODS: Prospective analysis was performed of 108 breast lesions 1 cm or smaller mammographically classified as BI-RADS 4/5 and 14 breast lesions larger than 2 cm mammographically classified as BI-RADS 5.
  • 33 of the 108 breast lesions 1 cm or smaller underwent sonographic core cut breast biopsy (group 1) and 75 stereotactic vacuum-assisted breast biopsy (group 2).
  • All 14 lesions greater than 2 cm were stereotactically vacuum-assisted breast biopsied (group 3).
  • Mammographies were performed in all patients of group 1 and 2 with a histologically benign finding (n = 31, n = 69, respectively) and in all patients of group 3 directly after clip placement and after 6 and 12 months.
  • RESULTS: Two patients of group 1 and 6 patients of group 2 had breast conservative surgery (BET) because of the histological diagnosis of a ductal carcinoma in situ or invasive breast cancer.
  • The tissue marker clips of the remaining 31 patients of group 1 and 69 patients of group 2 diverged with a mean value of 0.4 cm (standard deviation +/- 0.23 cm; range 0.1 cm to 0.9 cm) from their placement position after 6 months.
  • After 12 months the marker clips deviated with a mean value of 0.4 cm (standard deviation +/- 0.21 cm; range 0.1 cm to 0.9 cm) in 94 patients and 0.8 cm (standard deviation +/- 0.25 cm; range 0.1 cm to 0.9 cm) in 6 patients from their original location.
  • In all patients of group 3 the tissue marker clips were the only possibility to localize the tumour after neoadjuvant chemotherapy as all other diagnostic methods showed inconsistent results.
  • CONCLUSION: Positioning a tissue marker clip in the tumour centre seems to be reasonable after interventional biopsy of breast lesions of 1.0 cm or smaller and before neoadjuvant chemotherapy.
  • [MeSH-major] Biopsy, Needle / methods. Breast / pathology. Breast Diseases / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Follow-Up Studies. Humans. Reproducibility of Results. Surgical Instruments

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11997863.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


88. Nio Y, Dong M, Iguchi C, Yamasawa K, Toga T, Itakura M, Tamura K: Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J Surg Oncol; 2001 Mar;76(3):188-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy.
  • The present study was designed to assess the significance of p53 and Bcl-2 protein (pBcl-2) expression on resectable invasive ductal carcinoma (IDC) of the pancreas.
  • On the other hand, there were no differences in the survival curve between the adjuvant chemotherapy (ACT) group and the surgery alone (SA) group. pBcl-2 expression had no influence on the effect of ACT, the ACT group showed a significantly better survival than the SA group for p53(+) IDC patients.
  • CONCLUSIONS: pBcl-2 expression is a beneficial prognostic factor for patients with IDC, whereas p53 expression may be beneficial in the prediction of the effects of adjuvant chemotherapy on patients with IDC. J. Surg. Oncol. 2001;76:188-196.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / drug therapy. Carcinoma, Pancreatic Ductal / metabolism. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal. Chemotherapy, Adjuvant. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Proportional Hazards Models. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11276023.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


89. Takamura M, Nio Y, Yamasawa K, Dong M, Yamaguchi K, Itakura M: Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs; 2002 Jan;13(1):75-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives.
  • Thymidine synthase (TS) is a key enzyme in the synthesis of pyrimidine in the de novo pathway of DNA synthesis and a major target of 5-fluorouracil (5-FU), but the implications of TS regarding human pancreatic cancer have not been reported.
  • We assessed the expression of TS in invasive ductal carcinoma (IDC) of the pancreas by immunostaining and evaluated its clinicopathological significance, especially its implications regarding the efficacy of chemotherapy with 5-FU or its derivatives.
  • The implications of TS immunoreactivity regarding the efficacy of 5-FU-based adjuvant chemotherapy (ACT) was also assessed.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Carcinoma, Pancreatic Ductal / enzymology. Fluorouracil / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / enzymology. Thymidylate Synthase / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate. Tissue Distribution. Treatment Outcome

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11914644.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


90. Milowsky MI, Rosmarin A, Tickoo SK, Papanicolaou N, Nanus DM: Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer; 2002 Jan 1;94(1):111-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature.
  • BACKGROUND: Collecting (Bellini) duct carcinoma (CDC) of the kidney is associated with an aggressive course and an extremely poor prognosis.
  • To the authors' knowledge, there are no standard treatment regimens and neither immunotherapy nor chemotherapy have been found to be effective.
  • METHODS: In the current study, the authors report a 49-year-old man who presented with a 7.0 cm x 6.0 cm renal mass with extensive regional, paraaortic, and left supraclavicular lymphadenopathy.
  • Computed tomography (CT) scan after the third cycle revealed a significant (68%) reduction in the tumor volume.
  • After Cycle 6, a repeat CT scan demonstrated minimal disease progression.
  • Based on recent Phase II data of an active regimen comprised of AG alternating with ifosfamide, paclitaxel, and cisplatin (ITP) in patients with transitional cell carcinoma, the patient was treated with ifosfamide, 1500 mg/m(2) (Days 1-3); paclitaxel, 175 mg/m(2) (Day 1); and cisplatin, 35 mg/m(2) (Days 1 and 2), every 4 weeks with GCSF support.
  • After two cycles of ITP, the patient developed disease progression in bone and received palliative radiation therapy.
  • The patient received palliative care without further chemotherapy and died approximately 10 months after the initial diagnosis of CDC.
  • CONCLUSIONS: Immunohistologic and molecular analyses indicate that CDC more closely resembles transitional cell carcinoma than renal cell carcinoma.
  • Chemotherapy regimens used to treat advanced transitional cell carcinoma such as AG should be evaluated as first-line therapy for CDC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11815966.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA85609
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; TIP regimen
  • [Number-of-references] 16
  •  go-up   go-down


91. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T, Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer; 2002 Oct 15;95(8):1685-95
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
  • BACKGROUND: To the authors' knowledge, the significance of postoperative adjuvant chemotherapy in pancreaticobiliary carcinoma has not yet been clarified.
  • A randomized controlled study evaluated the effect of postoperative adjuvant therapy with mitomycin C (MMC) and 5-fluorouracil (5-FU) (MF arm) versus surgery alone (control arm) on survival and disease-free survival (DFS) for each specific disease comprising resected pancreaticobiliary carcinoma (pancreatic, gallbladder, bile duct, or ampulla of Vater carcinoma) separately.
  • METHODS: Between April 1986 and June 1992, a total of 508 patients with resected pancreatic (n = 173), bile duct (n = 139), gallbladder (n = 140), or ampulla of Vater (n = 56) carcinomas were allocated randomly to either the MF group or the control group.
  • ]) at the time of surgery and 5-FU (310 mg/m(2) i.v.) in 2 courses of treatment for 5 consecutive days during postoperative Weeks 1 and 3, followed by 5-FU (100 mg/m(2)orally) daily from postoperative Week 5 until disease recurrence.
  • RESULTS: After ineligible patients were excluded, 158 patients with pancreatic carcinoma (81 in the MF group and 77 in the control group), 118 patients with bile duct carcinoma (58 in the MF group and 60 in the control group), 112 patients with gallbladder carcinoma (69 in the MF group and 43 in the control group), and 48 patients with carcinoma of the ampulla of Vater (24 in the MF group and 24 in the control group) were evaluated.
  • Good compliance (> 80%) was achieved with MF treatment.
  • The 5-year survival rate in gallbladder carcinoma patients was significantly better in the MF group (26.0%) compared with the control group (14.4%) (P = 0.0367).
  • Similarly, the 5-year DFS rate of patients with gallbladder carcinoma was 20.3% in the MF group, which was significantly higher than the 11.6% DFS rate reported in the control group (P = 0.0210).
  • Significant improvement in body weight compared with the control was observed only in patients with gallbladder carcinoma.
  • There were no apparent differences in 5-year survival and 5-year DFS rates between patients with pancreatic, bile duct, or ampulla of Vater carcinomas.
  • The most commonly reported adverse drug reactions were anorexia, nausea/emesis, stomatitis, and leukopenia, none of which were noted to be serious.
  • CONCLUSIONS: The results of the current study indicate that gallbladder carcinoma patients who undergo noncurative resections may derive some benefit from systemic chemotherapy.
  • However, alternative modalities must be developed for patients with carcinomas of the pancreas, bile duct, or ampulla of Vater.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / drug therapy. Gallbladder Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Male. Middle Aged. Mitomycins / administration & dosage. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • [CommentIn] Cancer Treat Rev. 2003 Apr;29(2):135-7 [12670458.001]
  • (PMID = 12365016.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mitomycins; U3P01618RT / Fluorouracil; FuMi protocol
  •  go-up   go-down


92. Okamoto T, Goto M, Tomita I, Murayama A, Sawa M, Noguchi Y, Shimizu A: [A case of recurrence of breast cancer 36 years after mastectomy treated with endocrine and chemotherapy]. Gan To Kagaku Ryoho; 2010 May;37(5):899-902
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrence of breast cancer 36 years after mastectomy treated with endocrine and chemotherapy].
  • In 2001, a 72-year-old woman, who had undergone left mastectomy for breast carcinoma 36 years ago, was admitted because of dysphagia.
  • Chest CT showed pleural effusion in the right side and no tumor in the breast.
  • Cytology of chest effusion revealed adenocarcinoma.
  • She was diagnosed with a pleural recurrence of breast cancer, so administration of CAF agents (4 courses) was started.
  • She was then clinically followed on medication with oral anastrozole (AI).
  • After 4 years, progression of disease was noted.
  • The tumor was removed under local anesthesia and pathological findings showed invasive ductal carcinoma expressing estrogen receptor.
  • Chemotherapy with taxane had to be withdrawn because of its side effect.
  • Administration of S-1 was then started.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Ductal, Breast / drug therapy
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans. Mastectomy. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / radiography. Recurrence. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495324.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


93. Smith IE, A'Hern RP, Coombes GA, Howell A, Ebbs SR, Hickish TF, O'Brien ME, Mansi JL, Wilson CB, Robinson AC, Murray PA, Price CG, Perren TJ, Laing RW, Bliss JM, TOPIC Trial Group: A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol; 2004 May;15(5):751-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial.
  • BACKGROUND: To compare the efficacy of continuous infusional 5-fluorouracil (5-FU)-based chemotherapy against conventional bolus chemotherapy in the preoperative treatment of patients with large operable early breast cancer.
  • PATIENTS AND METHODS: Four hundred and twenty-six women with histologically proven 3 cm invasive early breast cancer were randomised to receive pre-operative infusional 5-FU 200 mg/m(2) by daily 24 h continuous infusion via a Hickman line for 18 weeks with epirubicin 60 mg/m(2) intravenous (i.v.) bolus on day 1 and cisplatin 60 mg/m(2) i.v. bolus on day 1, both repeating 3-weekly (infusional ECisF), or conventional bolus doxorubicin 60 mg/m(2) i.v. on day 1 and cyclophosphamide 600 mg/m(2) i.v. on day 1, both repeating 3-weekly (AC), both schedules for six courses.
  • Patients subsequently had local therapy (surgery or radiotherapy or both) and tamoxifen 20 mg orally daily as appropriate.
  • RESULTS: The 5 year results for AC and infusional ECisF, respectively, were as follows: overall response, 75% and 77%; complete clinical remission, 31% and 34%; pathological complete remission (pathCR), 16% for both; and pathCR with residual ductal carcinoma in situ (DCIS), 25% and 24%.
  • Both treatments were well tolerated.
  • CONCLUSIONS: Preoperative continuous infusional 5-FU-based chemotherapy is no more active than conventional AC for early breast cancer; with a median 5 year follow-up, the infusion-based schedule shows a non-significant trend towards improved survival.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15111342.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


94. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE: Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol; 2006 Jul;59(7):729-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
  • BACKGROUND: Grade-III invasive ductal carcinomas of no special type (IDCs-NST) constitute a heterogeneous group of tumours with different clinical behaviour and response to chemotherapy.
  • Patients with basal-like breast carcinomas (BLBC) are reported to have a shorter disease-free and overall survival.
  • Histological features, immunohistochemical findings for oestrogen receptor (ER), progesterone receptor (PgR) and HER2, and clinical outcome and survival after adjuvant chemotherapy were compared between the two groups.
  • Patients with BLBCs were found to have a significantly higher recurrence rate (p<0.05) and were associated with significantly shorter disease-free and overall survival (both p<0.05).
  • In the group of patients who received anthracycline-based adjuvant chemotherapy (BLBC group, n = 47; controls, n = 49), both disease-free and overall survival were found to be significantly shorter in the BLBC group (p<0.05).
  • Standard adjuvant chemotherapy seems to be less effective in these tumours and new therapeutic approaches are indicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Keratins / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Prognosis. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Oct;30(10):1134-9 [10534158.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):1983-7 [10561248.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):197-202 [10680887.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):422-7 [11487275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):267-75 [11556756.001]
  • [Cites] Oncology. 2001;61 Suppl 2:67-72 [11694790.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1991-6 [12466114.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5 [14519755.001]
  • [Cites] J Pathol. 2004 Jun;203(2):661-71 [15141381.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):249-58 [15254720.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4793-8 [15269154.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5988-97 [15447982.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):814-9 [15510162.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):697-704 [7884430.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1474-81 [10334533.001]
  • [Cites] J Pathol. 1999 Jan;187(2):207-16 [10365096.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):26-35 [15332092.001]
  • [Cites] Cancer Sci. 2005 Jan;96(1):48-53 [15649255.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):340-50 [15818618.001]
  • [Cites] Breast Cancer Res. 2005;7(4):143-8 [15987465.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] J Pathol. 2005 Sep;207(1):1-13 [15957152.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1321-8 [15990899.001]
  • [Cites] Virchows Arch. 2005 Oct;447(4):688-94 [16012853.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2329-34 [17438091.001]
  • [CommentIn] J Clin Pathol. 2007 Aug;60(8):958 [17660346.001]
  • (PMID = 16556664.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC1860434
  •  go-up   go-down


95. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M: Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. Radiology; 2004 Nov;233(2):424-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T.
  • PURPOSE: To determine if changes in the concentration of choline-containing compounds (tCho) from before primary systemic therapy (PST) to within 24 hours after the first treatment enable prediction of clinical response in patients with locally advanced breast cancer.
  • MATERIALS AND METHODS: Sixteen women with biopsy-confirmed locally advanced breast cancer scheduled to undergo doxorubicin-based PST were recruited.
  • Magnetic resonance (MR) imaging and spectroscopy were performed at 4 T prior to treatment, within 24 hours after the first dose, and after the fourth dose.
  • Of the remaining 13 patients, four had inflammatory breast cancer, six had invasive ductal carcinoma, two had invasive lobular carcinoma, and one had mixed invasive ductal and lobular carcinoma.
  • CONCLUSION: These results suggest that the change in tCho concentration between baseline and 24 hours after the first dose of PST can serve as an indicator for predicting clinical response to doxorubicin-based chemotherapy in locally advanced breast cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Magnetic Resonance Spectroscopy. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15516615.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA92004; United States / NCI NIH HHS / CA / P30 CA77398; United States / NCRR NIH HHS / RR / RR00400; United States / NCRR NIH HHS / RR / RR08079
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


96. Jones RL, Lakhani SR, Ring AE, Ashley S, Walsh G, Smith IE: Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer; 2006 Feb 13;94(3):358-62
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.
  • Patients who have no residual invasive cancer following neoadjuvant chemotherapy for breast carcinoma have a better overall survival than those with residual disease.
  • Many classification systems assessing pathological response to neoadjuvant chemotherapy include residual ductal carcinoma in situ (DCIS) only in the definition of pathological complete response.
  • The purpose of this study was to investigate whether patients with residual DCIS only have the same prognosis as those with no residual invasive or in situ disease.
  • A retrospective analysis of a prospectively maintained database identified 435 patients, who received neoadjuvant chemotherapy for operable breast cancer between February 1985 and February 2003.
  • Of these, 30 (7%; 95% CI 5-9%) had no residual invasive disease or DCIS and 20 (5%; CI 3-7%) had residual DCIS only.
  • With a median follow-up of 61 months, there was no statistical difference in disease-free survival, 80% (95% CI 60-90%) in those with no residual invasive or in situ disease and 61% (95% CI 35-80%) in those with DCIS only (P=0.4).
  • No significant difference in 5-year overall survival was observed, 93% (95% CI 75-98%) in those with no residual invasive or in situ disease and 82% (95% CI 52-94%) in those with DCIS only (P=0.3).
  • Due to the small number of patients and limited number of events in each group, it is not possible to draw definitive conclusions from this study.
  • Further analyses of other databases are required to confirm our finding of no difference in disease-free and overall survival between patients with residual DCIS and those with no invasive or in situ disease following neoadjuvant chemotherapy for breast cancer.
  • [MeSH-major] Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm, Residual. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] J Am Coll Surg. 1995 Mar;180(3):297-306 [7874340.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):547-52 [7884414.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):862-6 [9291806.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):93-100 [9440728.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):621-6 [9484820.001]
  • [Cites] Cancer J Sci Am. 1998 Jul-Aug;4(4):230-6 [9689981.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(30):96-102 [11773300.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1041-6 [11953845.001]
  • [Cites] Breast. 2003 Oct;12(5):320-7 [14659147.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2303-12 [15197191.001]
  • [Cites] Am J Clin Oncol. 1993 Jun;16(3):223-8 [8338056.001]
  • (PMID = 16421590.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361141
  •  go-up   go-down


97. Cayre A, Cachin F, Maublant J, Mestas D, Feillel V, Ferrière JP, Kwiaktowski F, Chevillard S, Finat-Duclos F, Verrelle P, Penault-Llorca F: Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. Int J Oncol; 2002 May;20(5):1049-55
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression.
  • We examined the relevance of a pre-treatment single static view 99mTc-sestamibi scintimammography and expression of multidrug resistance proteins as predictors of response to neoadjuvant chemotherapy for invasive breast cancer.
  • Forty-five patients affected by primary breast cancer underwent clinical examination, mammography, sonography, 99mTc-sestamibi scintimammography, and biopsy for histopathological diagnosis before neoadjuvant chemotherapy.
  • Following completion of anthracycline-based chemotherapy, clinical, mammographic, sonographic and pathological responses were determined.
  • A negative 99mTc-sestamibi scintimammography predicted chemoresistance with a specificity of 100%.
  • Uptake of 99mTc-sestamibi was inversely correlated to the expression of MDR1 (p<0.05) in invasive ductal carcinoma.
  • A pre-treatment single-view 99mTc-sestamibi scintimammography is an excellent predictor of MDR1 chemoresistance and was highly specific of a lack of pathological response to chemotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Chemotherapy, Adjuvant. Mammography / methods. Membrane Glycoproteins. Technetium Tc 99m Sestamibi / pharmacology
  • [MeSH-minor] Adult. Aged. Antigens, CD / biosynthesis. Antigens, CD9. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. P-Glycoprotein / biosynthesis. Phenotype. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11956603.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD9; 0 / CD9 protein, human; 0 / Membrane Glycoproteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


98. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP: Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer; 2004 Oct 1;101(7):1545-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
  • BACKGROUND: Immunotherapy is generally ineffective in patients with sarcomatoid renal cell carcinoma (RCC) and in patients with rapidly progressive metastatic or locally recurrent disease, with a median time to progression of approximately 2 months and a median survival of 4-7 months.
  • Based on the antitumor activity of doxorubicin and gemcitabine in collecting duct carcinoma of the kidney, the authors used this combination to treat selected patients with sarcomatoid or rapidly progressing RCC.
  • Seven patients received previous treatment with interferon or interleukin-2.
  • Sites of metastases included the lung, soft tissue, bone, liver, and brain with 88% of patients having > or = 3 sites of disease.
  • Treatment consisted of doxorubicin (50 mg/m2) and gemcitabine (1500 or 2000 mg/m2) every 2-3 weeks with granulocyte-colony-stimulating factor support.
  • Therapy was well tolerated with no Grade 4 toxicities.
  • Two patients had a complete response, five had a partial response, three had a mixed response, and one had stable disease.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Renal Cell / drug therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Doxorubicin / administration & dosage. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15378501.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Recombinant Proteins; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


99. Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, Nalcioglu O, Su MY: MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer; 2008 Jan 1;112(1):17-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
  • BACKGROUND: This study investigated the role of magnetic resonance imaging (MRI) in evaluation of pathologically complete response and residual tumors in patients who were receiving neoadjuvant chemotherapy (NAC) for both positive and negative HER-2 breast cancer.
  • On the basis of the final MRI, response was determined to be a clinically complete response ([CCR], no enhancement), probable CCR (residual enhancement equal to or less than that of glandular tissue), or residual tumor.
  • Pathological outcomes were categorized as 1) no residual cancer, 2) no residual invasive cancer but ductal carcinoma in situ (DCIS) present, or 3) residual invasive cancer.
  • The pathologically complete response (pCR) was defined as no invasive cancer.
  • The accuracy of MRI in identifying pCR varied according to the chemotherapy agent that was administered.
  • The high false-negative rate found in HER-2 negative patients was associated with residual disease that presented as scattered cells or small foci.
  • Results indicate that the chemotherapy agent should be taken into consideration when using MRI to interpret therapeutic outcomes.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • [ErratumIn] Cancer. 2008 Apr 1;112(7):1642. Feig, Byon [corrected to Feig, Byron]
  • (PMID = 18000804.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA062203; United States / NCI NIH HHS / CA / CA90437
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


100. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C: Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol; 2004 Aug;14(8):1371-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy.
  • The accuracy of mammography, sonography and magnetic resonance imaging (MRI) in identifying residual disease after neoadjuvant chemotherapy is evaluated and imaging findings are correlated with pathologic findings.
  • Fifteen patients enrolled in an experimental protocol of preoperative neoadjuvant chemotherapy underwent clinical examination, mammography, sonography and dynamic MRI, performed in this order, before and respectively after 2 and 4 cycles of neoadjuvant chemotherapy.
  • %) clinically complete response (CR), 9/15 (60%) partial response (PR), 3/15 (20%) stable disease (SD) and 1/15 (6.7%) progressive disease.
  • Mammography identified 1/15 (6.7%) clinically CR, 8/15 (53.3%) PR and 4/15 (27%) SD, and was not able to evaluate the disease in 2/15 (13%) cases.
  • Therefore, MRI and sonography compared to mammography correctly identified residual disease in 100 vs. 86%.
  • MRI resulted in two false-negative results because of the presence of microfoci of in situ ductal carcinoma (DCIS) and invasive lobular carcinoma (LCI).
  • MRI was superior to mammography in cases of multifocal or multicentric disease (83 vs. 33%).
  • Sonography performed after MRI improves the accuracy in evaluation of uncertain foci of multifocal disease seen on MR images with an increase of diagnostic accuracy from 73 to 84.5%.
  • MRI assesses response to neoadjuvant chemotherapy better than traditional methods of physical examination and mammography.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Lobular / diagnosis. Magnetic Resonance Imaging / methods. Neoadjuvant Therapy. Neoplasm, Residual / diagnosis. Ultrasonography, Mammary / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jan;17(1):110-9 [10458224.001]
  • [Cites] Radiology. 1995 Dec;197(3):743-7 [7480749.001]
  • [Cites] AJR Am J Roentgenol. 1999 Oct;173(4):911-7 [10511147.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Hong Kong Med J. 2000 Sep;6(3):265-8 [11025844.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(5):949-60 [1639655.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):537-40 [7884412.001]
  • [Cites] Br J Radiol. 1997 May;70(833):452-8 [9227225.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):416-23 [8004615.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):547-52 [7884414.001]
  • [Cites] Clin Radiol. 1993 May;47(5):339-44 [8508597.001]
  • [Cites] Radiology. 1993 May;187(2):493-501 [8475297.001]
  • [Cites] Radiology. 1999 Dec;213(3):881-8 [10580970.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):417-24 [9242745.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):91-100 [8646731.001]
  • [Cites] Radiology. 1996 Feb;198(2):333-40 [8596827.001]
  • [Cites] J Comput Assist Tomogr. 1997 Sep-Oct;21(5):773-9 [9294574.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] Radiology. 1996 Feb;198(2):327-32 [8596826.001]
  • [Cites] Radiology. 1994 Jun;191(3):633-8 [8184039.001]
  • [Cites] Radiology. 1989 Apr;171(1):95-103 [2648479.001]
  • [Cites] Eur Radiol. 2002 Jul;12(7):1711-9 [12111062.001]
  • [Cites] J Cancer Educ. 2002 Fall;17(3):138-41 [12243218.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):681-6 [2916021.001]
  • [Cites] Radiol Med. 1998 May;95(5):449-55 [9687919.001]
  • (PMID = 14986052.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement